Here you are: IMGT Web resources > IMGT Education > Tutorials

Translocations chromosomiques et cancer

Géraldine GUASCH

U119 INSERM Laboratoire d'Oncologie Moléculaire
27 Bd Leï Roure 13009 Marseille
Citer cet article
Liste des figures
Lien vers l'article

Références bibliographiques

A

Abruzzo L.V., Jaffe E.S., Cotelingam J.D., Whang-Peng J., Del Luca V., Medeiros L.J., 1992
T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy.
Am. J. Surg. Pathol. 16: 236-245.

Adams J.M., Cory S., 2001
Life-or-death decisions by the Bcl-2 protein family.
Trends. Biochem. Sci. 26: 61-66.

Adnane J., Gaudray P., Dionne C.A., Crumley G., Jaye M., Schlessinger J., Jeanteur P., Birnbaum D., Theillet C., 1991
BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers.
Oncogene. 6: 659-663.

Afar D.E.H., Han L., McLaughlin J., Wong S., Dhaka A., Parmar K., Rosenberg N., Witte O.N., Colicelli J., 1997
Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1.
Immunity. 6: 773-782.

Aguiar R.C.T., Chase A., Coulthard S., MacDonald D.H.C., Carapeti M., Reiter A., Sohal J., Lennard A., Goldman J.M., Cross N.C.P., 1997
Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement.
Blood. 90: 3130-3135.

Akagi T., Shishido T., Murata K., Hanafusa H., 2000
v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation.
Proc. Natl. Acad. Sci. 97: 7290-7295.

Albitar M., Freireich E.J., 2000
Molecular defects in chronic myeloproliferative disorders.
Mol. Med. 6: 555-567.

Alexander W.S., Nicola N.A., 1998
Hemopoietic growth factor receptor abnormalities in leukemia.
Leukemia Res. 22: 1097-1111.

Allouche M., 1995
Basic fibroblast growth factor and hematopoiesis.
Leukemia. 9: 937-942.

Anderson J., Burns HD., Enriquez-Harris P., Wilkie AO., Heath JK., 1998
Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand.
Hum. Mol. genet. 7: 1475-1483.

Aoki M., Blazek E., Vogt P.K., 2001
A role of the kinase mTOR in cellular transformation induced by the oncoprotein P3k and Akt.
Proc. Natl. Acad. Sci. 98: 136-141.

Arese M., Chen Y., Florkiewicz R.Z., Gualandris A., Shen B., Rifkin D.B., 1999
Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals.
Mol. Cell. Biol. 10: 1429-1444.

Arnould C., Philippe C., Bourdon V., Gregoire M.J., Berger R., Jonveaux P., 1999
The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia.
Hum. Mol. Genet. 8: 1741-1749.

B

Bai R-Y., Dieter P., Peschel C., Morris S.W., and Duyster J., 1998
Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity.
Mol. Cell. Biol. 18: 6951-6961.

Bai R-Y., Ouyang T., Miething C., Morris S.W., Peschel C., Duyster J., 2000
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.
Blood. 96: 4319-4327.

Balmain A., 2001
Cancer genetics: from Boveri and Mendel to microarrays
Nature reviews. 1: 77-82.

Barker S.A., Lujan D., Wilson B.S., 1999
Multiple roles for PI 3-kinase in the regulation of PLCg activity and Ca2+ mobilization in antigen-stimulated mast cells.
J. Leuk. Biol. 65: 321-329.

Barkett M., Gilmore T.D., 1999
Control of apoptosis by Rel/NF-κ B transcription factors.
Oncogene. 18: 6910-6924.

Barlund M., Monni O., Kononen J., Cornelison R., Torhorst J., Sauter G., Kallioniemi O.P., Kallioniemi A., 2000
Multiple genes at 17q23 undergo amplification and overexpression in breast cancer.
Cancer Res. 60: 5340-5344.

Barr FG., 1998
Translocations, cancer and the puzzle of specificity.
Nature Genet. 19: 121-124.

Behringer D., Schaefer H.E., Kunzmann R., Mertelsmann R., Dölken G., 1995
Translocation t(8;13) in a patient with T cell lymphoma and features of a myeloproliferative syndrome.
Leukemia. 9: 988-992.

Beiman M., Shilo B-Z., Volk T., 1996
Heartless, a drosophila FGF receptor homolog, is essential for cell migration and establishment of several mesodermal lineages.
Genes Dev. 10: 2993-3002.

Bellot F., Crumley G., Kaplow J.M., Schlessinger J., Jaye M., and Dionne C.A., 1991
Ligand-induced transphosphorylation between different FGF receptors.
EMBO J. 10: 2849-2854.

Bellus GA., McIntosh I., Smith EA., Aylsworth AS., Kaitila I., Horton WA., Greenhaw GA., Hecht JT., Francomano CA., 1995
A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.
Nature Genet. 10: 357-359.

Bellus G.A., Gaudenz K., Zackai E.H., Clarke L.A., Szabo J., Francomano C.A., Muenke M., 1996
Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes
Nature Genet. 14: 174-176.

Bellus G.A., Bamshad M.J., Przylepa K.A., Dorst J., Lee R.R., Hurko O., Jabs E.W., Curry C.J., Wilcox W.R., Lachman R.S., Rimoin D.L., Francomano C.A., 1999
Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.
Am. J. Med. Genet. 85: 53-65.

Bennet J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D., Gralnick H.R., and Sultan C., 1985
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.
Ann. Of Int. Med. 103: 626-629.

Berardi A.C., Wang A., Abraham J., Scaden D.T., 1995
Basic fibroblast growth factor mediates its effects on committed myeloid progenitors by direct action and has no effect on hematopoietic stem cells.
Blood. 86: 2123-2129.

Besançon F., Atfi A., Gespach C., Cayre Y.E., Bourgeade M.F., 1998
Evidence for a role of NF-κ B in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor β fusion protein.
Proc. Natl. Acad. Sci. 95: 8081-8086.

Beviglia L., Matsumoto K., Lin C.S., Ziober B.L., Kramer R.H., 1997
Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression
Int. J. Cancer. 74: 301-309.

Biernaux C., Loos M., Sels A., Huez G., Stryckmans P., 1995
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.
Blood. 86: 3118-3122.

Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., Gil Diez de Medina S., Van Rhijn B., Bralet M.P., Lefrere-Belda M.A., Lahaye J.B., Abbou C.C., Bonaventure J., Zafrani E.S., van der Kwast T., Thiery J.P., Radvanyi F., 2001
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
Am. J. Pathol. 158: 1955-1959.

Blume-Jensen P., Hunter T., 2001
Oncogenic kinase signalling.
Nature. 411: 355-365.

Bodine D.M., Karlsson S., Nienhuis A.W., 1989
Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells.
Proc. Natl. Acad. Sci. 86: 8897-8901.

Boget S., Cereser C., Parvaz P., Leriche A., Revol A., 2001
Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are not.
Eur. J. Endocrinol. 145: 303-310.

Bonfini L., Migliaccio E., Pelicci G., Lanfrancone L., Pelicci P., 1996
Not all shc’s roads lead to ras.
Trends Biochem. Sci. 21: 257-261.

Borg JP., Ooi J., Levy E., Margolis B., 1996
The PI domain of X11 and FE65 bind to distinct site on the YENPTY motif of amyloid precursor protein.
Mol. Cell. Biol. 16: 6229-6241.

Borrello M.G., Alberti L., Arighi E., Bongarzone I., Battistini C., Bardelli A., Pasini B., Piutti C., Rizzetti M.G., Mondellini P., Radice M.T., Pierotti M.A., 1996
The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cγ.
Mol. Cell. Biol. 16: 2151-2163.

Borrow J., Stanton V.P., Andresen J.M., Becher R., Behm F.G., Chaganti R.S.K., Civin C.I., Disteche C., Dubé I., Frischauf A.M., Horsman D., Mitelman F., Volinia S., Watmore A.E., Housman D.E., 1996a
The translocation t(8;16)(p11;p13) of acute myeloid leukemia fuses a putative acetyl transferase to the CREB-binding protein.
Nat. Genet. 14: 33-41.

Borrow J., Shearman AM., Stanton V.P., Becher R., Collins T., Williams AJ., Dubé I., Katz F., Kwong YL., Morris C., Ohyashiki K., Toyama K., Rowley J., Housman D.E., 1996b
The t(7;11)(p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9.
Nat. Genet. 12: 159-167.

Bose S., Deininger M., Gora-Tybor J., Goldman JM., Melo J.V., 1998
The presence of typical and atypical BCR-ABL fusion genes in leucocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease.
Blood. 92: 3362-3367.

Bottaro D.P., Rubin J.S., Ron D., Finch P.W., Florio C., Aaronson S.A., 1990
Characterization of the receptor for keratinocyte growth factor.
J. Biol. Chem. 265: 12767-12770.

Bowman T., Garcia R., Turkson J., Jove R., 2000
STATs in oncogenesis.
Oncogene. 19: 2474-2488.

Brazil D.P., Hemmings B.A., 2001
Ten years of protein kinase B signalling: a hard Akt to follow.
Trends in Biochem. Sci. 26: 657-664.

Bromberg J.F., 2001
Activation of STAT proteins and growth control.
BioEssays. 23: 161-169.

Broutin I., Ducruix A., 2000
Domaines structuraux et signalisation.
Medecine/Sciences. 16: 611-616.

Browaeys-Poly E., Cailliau K., Vilain J.P., 2000
Signal transduction pathways triggered by fibroblast growth factor receptor 1 expressed in Xenopus laevis oocytes after fibroblast growth factor 1 addition.
Eur. J. Biochem. 267: 6256-6263.

Brown D., Kogan S., Lagasse E., Weissman I., Alcalay M., Pelicci P.G., Atwater S., Bishop J.M., 1997
A PMLRARα transgene initiates murine acute promyelocytic leukemia.
Proc. Natl. Acad. Sci. 94: 2551-2556.

Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E., 1999
Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor.
Cell. 96: 857-868.

Brunn G.J., Hudson C.C., Sekulic A., Williams J.M., Hosoi H., Houghton P.J., Lawrence J.C., Abraham R.T., 1997
Phosphorylation of the translational repressor PHAS-1 by the mammalian target of rapamycin.
Science. 277: 99-101.

Burel SA., Harakawa N., Zhou L., Pabst T., Tenen DG., Zhang D., 2001
Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation.
Mol. Cell. Biol. 16: 5577-5590.

Burgar H.R., Burns H.D., Elsden J.L., Lalioti M.D., Heath J.K., 2001
Association of the signalling adaptor FRS2 with fibroblast growth factor receptor 1 (Fgfr1) is mediated by alternative splicing of the juxtamembrane domain.
J. Biol. Chem. in press.

Burgering B.M.Th. Coffer P.J., 1995
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.
Nature. 376: 599-602.

Burgess W.H., Dionne C.A., Kaplow J., Mudd R., Friesel R., Zilberstein A., Schlessinger J., Jaye M., 1990
Characterization and cDNA cloning of phospholipase C-γ, a major substrate for heparin-binding growth factor 1 (acidic fibroblast growth factor)-activated tyrosine kinase.
Mol. Cell Biol. 10: 4770-4777.

Burke D., Wilkes D., Blundell TL., Malcolm S., 1998
Fibroblast growth factor receptors: lessons from the genes.
Trends Biochem. Sci. 23: 59-62.

Butti M.G., Bongarzone I., Ferraresi G., Mondellini P., Borrello M.G., Pierotti M.A., 1995
A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas.
Genomics. 28: 15-24.

C

Cantley L.C., Neel B.G., 1999
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.
Proc. Natl. Acad. Sci. 96: 4240-4245.

Cappellen D., De Oliveira C., Ricol D., de Medina S.G.D., Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F., 1999
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
Nature Genet. 23: 18-20.

Carapeti M., Aguiar R.C.T., Goldman J.M., Cross N.C.P., 1998
A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.
Blood. 91: 3127-3133.

Carballada R., Yasuo H., Lemaire P., 2001
Phosphatidylinositol-3 kinase acts in parallel to the ERK MAP kinase in the FGF pathway during Xenopus mesoderm induction.
Development. 128: 35-44.

Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., Reed J.C., 1998
Regulation of cell death protease caspase-9 by phosphorylation.
Science. 282: 1318-1321.

Carlesso N., Frank D.A., Griffin J.D., 1996
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
J.Exp. Med. 183: 811-820.

Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E., Wells S.A., Goodfellow P.J., Donis-Keller H., 1994
Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.
Proc. Natl. Acad. Sci. 91: 1579-1583.

Carpenter G., Ji Q-S., 1999
Phospholipase C-γ as a signal-transducing element.
Exp. Cell Res. 253: 15-24.

Carroll M., Tomasson M.H., Barker G.F., Golub T.R., and Gilliland. D.G., 1996
The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming kinase-dependent signaling pathways.
Proc. Natl. Acad. Sci. USA. 93: 14845-14850.

Carron C., Cormier F., Janin A., Lacronique V., Giovannini M., Daniel M.T., Bernard O., Ghysdael J., 2000
TEL-JAK2 transgenic mice develop T-cell leukemia.
Blood. 95: 3891-3899.

Casci T., Vinos J., Freeman M., 1999
Sprouty, an intracellular inhibitor of Ras signaling.
Cell. 96: 655-665.

Castellanos A., Pintado B., Weruaga E., Arévalo R., Lopez A., Orfao A., Sanchez-Garcia I., 1997
A BCR-ABL p190 fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product.
Blood. 90: 2168-2174.

Chaffanet M., Popovici C., Leroux D., Jacrot M., Adelaïde J., Dastugue N., Grégoire M-J., Lafage Pochitaloff M., Birnbaum D., and Pébusque M-J., 1998
t(6;8), t(8;9) and t(8;13) translocations associated with myeloproliferative disorders have close or identical breakpoints on chromosome 8p11-12.
Oncogene. 16: 945-949.

Chaffanet M., Mozziconacci M.J., Fernandez F., Sainty D., Lafage-Potchitaloff M., Birnbaum D., Pébusque M.J., 1999
A case of inv(8)(p11q24) associated with acute myeloid leukemia involves the MOZ and CBP genes in a masked t(8;16).
Genes Chrom. Cancer. 26: 161-165.

Chaffanet M., Gressin L., Preudhomme C., Soenen-Cornu V., Birnbaum D., Pébusque M.J., 2000
MOZ is fused to p300 in an acute monocytic leukemia with t(8;22).
Genes Chrom. Cancer. 28: 138-144.

Champagne N., Pelletier N., Yang X-J., 2001
The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase.
Oncogene. 20: 404-409.

Chang C.P., Jacobs Y., Nakamura T., Jenkins N.A., Copeland N.G., Cleary M.L., 1997
Meis proteins are major in vivo DNA binding partners for wild-type but not chimeric Pbx proteins.
Mol. Cell. Biol. 17: 5679-5687.

Chang L., Karin M., 2001
Mammalian MAP kinase signalling cascades.
Nature. 410: 37-40.

Charbord P., 1998
Le micro-environnement médullaire chez l’homme normal et pathologique.
Hématologie. 4: 29-40.

Chaudhuri MM., Moscatelli D., Basilico C., 1993
Involvement of the conserved acidic amino acid domain of FGF Receptor 1 in ligand-receptor interaction.
J. Cell. Physiol. 157: 209-216.

Chen Z., Brand N., Chen A., Chen S.J., Tong J.H., Wang Z.Y., Waxman S., Zelent A., 1993
Fusion between a novel kruppel-like zinc finger gene and the retinoic acid receptor a locus due to a variant t(11;17) translocation in acute promyelocytic leukemia.
EMBO J. 12: 1161-1167.

Chen Y., Li X., Eswarakumar V.P., Seger R., Lonai P., 2000
Fibroblast growth factor (FGF) signalling through PI 3-kinase and Akt/PKB is required for embryoid body differentiation.
Oncogene. 19: 3750-3756.

Cheng JQ., Ruggeri B., Klein WM., Sonoda G., Altomare DA., Watson DK., Testa JR., 1996
Amplification of AKT2 in human pancreatic-cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.
Proc. Natl. Acad. Sci. USA. 93: 3636-3641.

Chernova O., Still I., Kalaycio M., Hoeltge G., Cowell J.K., 1998
Characterization of the breakpoints in a t(8;13)(p11;q12) translocation from a patient with myeloproliferative disease using fluorescence in situ hybridization.
Genes Chrom. Cancer. 21: 160-165.

Chesi M., Nardini E., Brents LA., Schrock E., Ried T., Kuehl WM., and Bergsagel PL., 1997
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
Nat. Genet. 16: 260-264.

Chesi M., Brents LA., Ely SA., Bais C., Robbiani DF., Mesri EA., Kuehl WM., and Bergsagel PL., 2001
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Blood. 97(3): 729-736.

Chou M.M., Blenis J., 1995
The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling
Cur. Op. Cell Biol. 7: 806-814.

Chu Z.L., McKinsey T.A., Liu L., Gentry J.J., Malim M.H., Ballard D.W., 1997
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control.
Proc. Natl. Acad. Sci. 94: 10057-10062.

Chung J., Grammer T.C., Lemon K.P., Kazlauskas A., Blenis J., 1994
PDGF- and insulin-dependent pp70S6K activation mediated by phosphatidylinositol-3-OH-kinase.
Nature. 370: 71-75.

Cirinnà M., Trotta R., Salomoni P., Kossev P., Wasik M., Perrotti D., Calabretta B., 2000
Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation.
Blood. 96: 3915-3921.

Cleary ML., 1991
Oncogenic conversion of transcription factors by chromosomal translocations.
Cell. 66: 619-622.

Cobaleda C., Pérez-Losada J., Sanchez-Garcia I., 1998
Chromosomal abnormalities and tumor development: from genes to therapeutic mechanisms.
BioEssays. 20: 922-930.

Coffer PJ., Jin J., Woodgett JR., 1998
Protein kinase B (c-AKT): a multifunctional mediator of phosphatidylinositol 3-kinase activation.
Biochem. J. 335: 1-13.

Cohen P., Frame S., 2001
The renaissance of GSK3.
Nature Mol. Cell. Biol. 2: 769-776.

Constantino Rosa Santos S., Dumon S., Mayeux P., Gisselbrecht S., Gouilleux F., 2000
Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line.
Oncogene. 19: 1164-1172.

Constantino Rosa Santos S., Lacronique V., Bouchaert I., Monni R., Bernard O., Gisselbrecht S., Gouilleux F., 2001a
Constitutively active STAT5 variants induce growyh and survival of hematopoietic cells through a PI3-kinase/Akt dependant pathway.
Oncogene. 20: 2080-2090.

Constantino Rosa Santos S., Monni R., Bouchaert I., Bernard O., Gisselbrecht S., Gouilleux F., Lacronique V., 2001b
Involvement of the NF-kB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein.
FEBS Letters. 497: 148-152.

Cortez D., Kadlec L., Pendergast A.M., 1995
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Mol. Cell. Biol. 15: 5531-5541.

Coulthard S., Chase A., Orchard K., Watmore A., Vora A., Goldman J.M., Swirsky D.M., 1998
Two cases of inv(8)(p11q13) in AML with erythrophagocytosis: a new cytogenetic variant.
Br. J. Haematol. 100: 561-563.

Coulier F., Pontarotti P., Roubin R., Hartung H., Goldfarb M., Birnbaum D., 1997
Of worms and men: an evoultionary perspective on the fibroblast growth factor (FGF) and FGF receptor familes.
J. Mol. Evol. 44: 43-56.

Craddock B.L., Orchiston E.A., Hinton H.J., Welham M.J., 1999
Dissociation of apoptosis from proliferation, protein kinase B activation, and BAD phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling.
J. Biol. Chem. 274: 10633-10640.

Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A., 1995
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.
Nature. 378: 785-789.

Cross M.J., Hodgkin M.N., Roberts S., Landgren E., Wakelam M.J.O., Claesson-Welsh L., 2000
Tyrosine 766 in the fibroblast growth factor receptor-1 is required for FGF-stimulation of phospholipase C, phospholipase D, phospholipase A2, phosphoinositide 3-kinase and cytoskeletal reorganisation in porcine aortic endothelial cells.
J. Cell Sci. 113: 643-651.

Cryns V., Yuan J., 1998
Proteases to die for.
Genes dev. 12: 1551-1570.

D

Daley G.Q., Van Etten R.A., Baltimore D., 1990
Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the philadelphia chromosome.
Science. 247: 824-830.

Dash A., Gilliland D.G., 2001
Molecular genetics of acute myeloid leukaemia.
Best Practice Res. Clin. Haematol. 14: 50-64.

Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E., 1997
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.
Cell. 91: 231-241.

Datta S.R., Brunet A., and Greenberg M.E., 1999
Cellular survival: a play in three Akts.
Genes Dev. 13: 2905-2927.

Datta S.R., Katsov A., Hu L., Petros A., Fesik S.W., Yaffe M.B., Greenberg M.E., 2000
14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation.
Mol. Cell. 6: 41-51.

Deininger M.W.N., Goldman J.M., and Melo J.V., 2000
The molecular biology of chronic myeloid leukemia.
Blood. 96: 3343-3356.

Dell’Era P., Mohammadi M., Presta M., 1999
Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis.
Mol. Biol. Cell. 10: 23-33.

Del Peso L., Gonzalez-Garcia M., Page C., Herrera R., Nunez G., 1997
Interleukin-3 induced phosphorylation of BAD through the protein kinase Akt.
Science. 278: 687-689.

Demiroglu A., Steer E.J., Heath C., Taylor K., Bentley M., Allen S.L., Koduru P., Brody J.P., Hawson G., Rodwell R., Doody M.L., Carnicero F., Reiter A., Goldman J.M., Melo J.V., Cross N.C.P., 2001
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
Blood. 98: 3778-3783.

Deng C.X., Wynshaw-Boris A., Shen M.M., Daugherty C., Ornitz D.M., Leder P., 1994
Murine FGFR1 is required for early postimplantation growth and axial organization.
Genes Dev. 8: 3045-3057.

Deng X., Ruvolo P., Carr B., May W.S., 2000
Survival function of ERK1/2 as IL-3-activated staurosporine-resistant Bcl2 kinases.
Proc. Natl. Acad. Sci. 97: 1578-1583.

Desmaze C., Brizard F., Turc-Carel C., Melot T., Delattre O., Thomas G., Aurias A., 1997
Multiple chromosomal mechanisms generate an EWS/FLI1 or EWS/ERG fusion gene in Ewing tumors.
Cancer Genet. Cytogenet. 97: 12-19.

Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C., 1998
IAPs block apoptotic events induced by caspase 8 and cytochrome c by direct inhibition of distinct caspases.
EMBO J. 17: 2215-2223.

DeVita Jr. V.T., and Canellos G.P., 1999
The Lymphomas.
Seminars in Hematol. 36 suppl.7: 84-94.

DeVore D.L., Horvitz H.R., Stern M.J., 1995
An FGF-receptor signaling pathway is required for the normal cell migrations of the sex myoblasts in C. elegans hermaphrodites.
Cell. 83: 611-620.

Dickstein J.I., and Vardiman J.W., 1995
Hematopathologic Findings in the Myeloproliferative Disorders.
Seminars in Oncol. 22: 355-373.

Dionne C.A., Crumley G., Bellot F., Kaplow J.M., Searfoss G., Ruta M., Burgess W.H., Jaye M., Schlessinger J., 1990
Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.
EMBO J. 9: 2685-2692.

Dominguez I., Green J.B.A., 2001
Missing links in GSK3 regulation.
Dev. Biol. 235: 303-313.

Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., Howe J.R., Moley J.F., Goodfellow P., Wells S.A., 1993
Mutations in the RET proto-oncogene are associated with MEN 2A and FTMC.
Hum. Mol. Genet. 2: 851-856.

Downward J., 1999
How BAD phosphorylation is good for survival.
Nat. Cell Biol. E33-E35.

Drexler H.G., MacLeod RAF., Borkhardt A., and Janssen JWG., 1995
Recurrent chromosomal translocations and fusion genes in leukemia-lymphoma cell lines.
Leukemia. 9: 480-500.

Druker B., 2001
Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia.
Semin. Hematol. 38: 9-14.

Dunican D.J., Williams E.J., Howell F.V., Doherty P., 2001
Selective inhibition of fibroblast growth factor (FGF)-stimulated mitogenesis by a FGF receptor-1-derived phosphopeptide.
Cell Growth Diff. 12: 255-264.

E

Elefanty A.G., Cory S., 1992
Hematologic disease induced in Balb/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Mol. Cell. Biol. 12: 1755-1763.

Elsner S., Martin H., Rode C., Wassmann B., Ganser A., Hoelzer D., 1994
An uncommon translocation t(6;8) associated with atypical acute myeloid leukemia/myeloproliferative disease detected by fluorescence in situ hybridization.
Br. J. Haematol. 87 (suppl. 1): 124.

Engels I.H., Stepczynska A., Stroh C., Lauber K., Berg C., Schwenzer R., Wajant H., Jänicke R.U., Porter A.G., Belka C., Gregor M., Schulze-Osthoff K., Wesselborg S., 2000
Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis.
Oncogene. 19: 4563-4573.

Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., Li Y., Wang J.M., Yang-Yen H.F., Karras J., Jove R., Loughran T.P., 2001
Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.
J. Clin. Investig. 107: 351-362.

Erhardt P., Schremser E.J., Cooper G.M., 1999
B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway.
Mol. Cell. Biol. 19: 5308-5315.

Evan G.I., Vousden K.H., 2001
Proliferation, cell cycle and apoptosis in cancer.
Nature. 411: 342-348.

Ezoe K., Holmes SA., Ho L., Bennett CP., Bolognia JL., Brueton L., Burn J., Falabella R., Gatto EM., Ishii N., Moss C., Pittelkow M.R., Thompson E., Ward A., Spritz R.A., 1995
Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism.
Am. J. Hum. Genet. 56: 58-66.

F

Fagan K., Hyde S., Harrison P., 1993
Translocation (8;13) and T-cell lymphoma. A case report.
Cancer Genet. Cytogenet. 65: 71-73.

Falasca M., Logan S.K., Lehto V.P., Baccante G., Lemmon M.A., Schlessinger J., 1998
Activation of phospholipase Cγ by PI 3-kinase- induced PH domain-mediated membrane targeting.
EMBO J. 17: 414-422.

Fan S., Ma Y.X., Gao M., Yuan R.Q., Meng Q., Goldberg I.D., Rosen E.M., 2001
The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signalling for cell survival and DNA repair.
Mol. Cell. Biol. 21: 4968-4984.

Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., Copeland R.A., Magolda R.L., Scherle P.A., Trzaskos J.M., 1998
Identification of a novel inhibitor of mitogen-activated protein kinase kinase.
J. Biol. Chem. 273: 18623-18632.

Feller S.M., 2001
Crk family adaptors-signalling complex formation and biological roles.
Oncogene. 20: 6348-6371.

Fenrick R., Amann J.M., Lutterbach B., Wang L., Westendorf J.J., Downing J.R., Hiebert S.W., 1999
Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.
Mol. Cell. Biol. 19: 6566-6574.

Ferracini R., Di Renzo M.F., Scotlandi K., Baldini N., Olivero M., Lollini P., Cremona O., Campanici M., Comoglio P.M., 1995
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit.
Oncogene. 10: 739-749.

Fioretos T., Panagopoulos I., Lassen C., Swedin A., Billström R., Isaksson M., Strömbeck B., Olofsson T., Mitelman F., Johansson B., 2001
Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
Genes Chrom. Cancer. 32: 302-310.

Fischer S., Gisselbrecht S., 1998
Inhibition de l’apoptose: une des fonctions de la kinase Akt/PKB.
Hématologie. 4: 102-106.

Flandrin G., 2001
La nouvelle classification OMS des hémopathies malignes.
Hématologie. 7: 136-141.

Fleming T.P., Saxena A., Clark W.C., Robertson J.T., Oldfield E.H., Aaronson S.A., Ali I.U., 1992
Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors.
Cancer Res. 52: 4550-4553.

Foehr E.D., Raffioni S., Murray-Rust J., Bradshaw R.A., 2001
The role of tyrosine residues in fibroblast growth factor receptor 1 signaling in PC12 cells.
J. Biol. Chem. 276: 37529-37536.

Forestell S.P., Dando J.S., Bohnlein E., Rigg R.J., 1996
Improved detection of replication-competent retrovirus.
J. Virol. Methods. 60: 171-178.

Franke T.F., Kaplan D.R., Cantley L.C., 1997a
PI3K: downstream AKTion blocks apoptosis.
Cell. 88: 435-437.

Franke T.F., Kaplan D.R., Cantley L.C., Toker A., 1997b
Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.
Science. 275: 665-668.

Friedhoff F., Rajendra B., Moody R., Alapatt T., 1983
Novel reciprocal translocation between chromosomes 8 and 9 found in a patient with myeloproliferative disorder.
Cancer Genet. Cytogenet. 9: 391-394.

G

Galvin B.D., Hart K.C., Meyer A.N., Webster M.K., Donoghue D.J., 1996
Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR) 2 and FGFR2/Neu chimeras.
Proc. Natl. Acad. Sci. 93: 7894-7899.

Geoerger B., Kerr K., Tang C.B., Fung K.M., Powell B., Sutton L.N., Phillips P.C., Janss A.J., 2001
Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
Cancer Research. 61: 1527-1532.

Gesbert F., Griffin J.D., 2000
Bcr/Abl activates transcription of the Bcl-X gene through STAT5.
Blood. 96: 2269-2276.

Gibbs J.B., Oliff A., Kohl N.E., 1994
Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.
Cell. 77: 175-178.

Gilliland D.G., 2001
Hematologic malignancies.
Curr. Op. Hematol. 8: 189-191.

Goga A., McLaughlin J., Afar D.E.H., Saffran D.C., Witte O.N., 1995
Alternative signals to Ras for hematopoietic transformation by the BCR-ABL oncogene.
Cell. 82: 981-988.

Goldfarb M., 1990
The fibroblast factor family.
Cell Growth Differ. 1: 439-445.

Golub T.R., Barker G.F., Lovett M., and Gilliland D.G., 1994
Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.
Cell. 77: 307-316.

Golub T., Barker G.F., Bohlander S., Hiebert S.W., Ward D.C., Bray-Ward P., Morgan E., Raimondi S.C., Rowley J.D., and Gilliland D.G., 1995
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Proc. Natl. Acad. Sci. 92: 4917-4921.

Golub T.R., Goga A., Barker G.F., Afar D.E., McLaughlin J., Bohlander S.K., Rowley J.D., Witte O.N., and Gilliland D.G., 1996
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.
Mol. Cell. Biol. 16: 4107-4116.

Golub T.R., Barker G.F., Stegmaier K., and Gilliland D.G., 1997
The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms.
Current Topics Microbiol. Immunol. 220: 67-79.

Gordon M.Y., Dazzi F., Marley S.B., Lewis J.L., Nguyen D., Grand F.H., Davidson R.J., and Goldman J.M., 1999
Cell biology of CML cells.
Leukemia. 13, suppl. 1: S65-S71.

Gorman D.M., Cotter T.G., 2001
Molecular signals in anti-apoptotic survival pathways.
Leukemia. 15: 21-34.

Grandis J.R., Drenning S.D., Zeng Q., Watkins S.C., Melhem M.F., Endo S., Johnson D.E., Huang L., He Y., Kim J.D., 2000
Constitutive activation of STAT3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.
Proc. Natl. Acad. Sci. 97: 4227-4232.

Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C., Della Porta G., 1992
TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.
Oncogene. 7: 237-242.

Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M., Pierotti M.A., 1995
The DNA rearrangement that generates TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.
Mol. Cell. Biol. 15: 6118-6127.

Grigelioniene G., Hagenas L., Eklof O., Neumeyer L., Haereid P.E., Anvret M., 1998
A novel missense mutation Ile258Val in the fibroblast growth factor receptor 3 in hypochondroplasia.
Hum. Mutat. 11: 333.

Grisolano J.L., Wesselschmidt R.L., Pelicci P.G., Ley T.J., 1997
Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences.
Blood. 89: 376-387.

Gross A., McDonnell JM., Korsmeyer S.J., 1999a
BCL-2 family members and the mitochondria in apoptosis.
Genes Dev. 13: 1899-1911.

Gross A.W., Zhang X., Ren R., 1999b
Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
Mol. Cell. Biol. 19: 6918-6928.

Gross I., Bassit B., Benezra M., Licht J.D., 2001
Mammalian Sprouty proteins inhibit cell growth and differentiation by preventing ras activation.
J. Biol. chem. 276: 46460-46468.

Gu H., Maeda H., Moon J.J., Lord J.D., Yoakim M., Nelson B.H., and Neel B.G., 2000
New Role for Shc in Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway.
Mol.Cell.Biol. 20: 7109-7120.

Guasch G., Mack G.J., Popovici C., Dastuge N., Birnbaum D., Rattner J.B., Pébusque M-J., 2000
FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).
Blood 95: 1788-1796.

H

Hadari YR., Kouhara H., Lax I., Schlessinger J., 1998
Binding of SHP2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation.
Mol. Cell. Biol. 18: 3966-3973.

Hadari YR., Gotoh N., Kouhara H., Lax I., Schlessinger J., 2001
Critical role for the docking- protein FRS2α in FGF receptor- mediated signal transduction pathways.
Proc. Natl. Acad. Sci. USA. 98: 8578-8583.

Haldar S., Jena N., Croce C.M., 1995
Inactivation of Bcl-2 by phosphorylation.
Proc. Natl Acad. Sci. 92: 4507-4511.

Hall H., Williams E.J., Moore S.E., Walsh F.S., Prochiantz A., Doherty P., 1996
Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide.
Current Biol. 6: 580-587.

Haluska FG., Tsujimoto Y., Croce CM., 1987
The t(8;14) chromosome translocation of the Burkitt lymphoma cell line Daudi occured during immunoglobulin gene rearrangement and involved the heavy chain diversity region.
Proc. Natl. Acad. Sci. USA. 84: 6835-6839.

Hamilton E., Miller K.M., Helm K.M., Langdon W.Y., Anderson S.M., 2001
Suppression of apoptosis induced by growth factor withdrawal by an oncogenic form of c-Cbl.
J. Biol. Chem. 276: 9028-9037.

Hanahan D., Weinberg R.A., 2000
The hallmarks of cancer.
Cell. 100: 57-70.

Hanenberg H., Xiao X.L., Dilloo D., Hashino K., Kato I., Williams D.A., 1996
Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells.
Nature Med. 2: 876-882.

Hanks S.K., and Hunter T., 1995
Protein kinases 6. The eukaryotic protein kinase superfamily : kinase (catalytic) domain structure and classification.
FASEB J. 9: 576-596.

Hannemann J.R., McManus D.M., Kabarowski J.H.S., Wiedemann L.M., 1998
Haemopoietic transformation by the TEL/ABL oncogene.
British. J. of Haematol. 102: 475-485.

Hara K., Yonezawa K., Sakaue H., Ando A., Kotani K., Kitamura T., Kitamura Y., Ueda H., Stephens L., Jackson T.R., Hawkins P.T., Dhand R., Clark A.E., Holman G.D., Waterfield M.D., Kasuga M., 1994
1-phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells.
Proc. Natl. Acad. Sci. 91: 7415-7419.

Hara K., Yonezawa K., Sakaue H., Kotani K., Kojima A., Waterfield M.D., Kasuga M., 1995
Normal activation of P70 S6 kinase by insulin in cells overexpressing dominant negative 85kD subunit of phosphoinositide 3-kinase.
Biochem. Biophys. Res. Commun. 208: 735-741.

Hara K., Yonezawa K., Kozlowski M.T., Sugimoto T., Andrabi K., Weng Q.P., Kasuga M., Nishimoto I., Avruch J., 1997
Regulation of elF-4E BP1 phosphorylation by mTOR.
J. Biol. Chem. 272: 26457-26463.

Hart K.C., Robertson S.C., Kanemitsu M.Y., Meyer A.N., Tynan J.A., Donoghue D.J., 2000
Transformation and STAT activation by derivatives of FGFR1, FGFR3 and FGFR4.
Oncogene. 19: 3309-3320.

Hart K.C., Robertson S.C., Donoghue D.J., 2001
Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.
Mol. Biol. Cell. 12: 931-942.

Hawley R.G., Lieu F.H.L., Fong A.Z.C., and Hawley T.S., 1994
Versatile retroviral vectors for potential use in gene therapy.
Gene Ther. 1: 136-138.

Hawley R.G., Fong A.Z.C., Ngan B.-Y., Hawley T.S., 1995
Hematopoietic transforming potential of activated ras in chimeric mice.
Oncogene. 11: 1113-1123.

He L.Z., Guidez F., Tribioli C., Peruzzi D., Ruthard M., Zelent A., Pandolfi P.P., 1998
Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL.
Nature Genet. 18: 126-135.

Hecht J.L., Aster J.C., 2000
Molecular biology of Burkitt’s lymphoma.
J. Clin. Oncol. 18: 3707-3721.

Heldin C.H., 1996
Protein tyrosine kinase receptors.
Cancer Surv. 27: 7-24.

Helou K., Wallenius V., Qiu Y., Öhman F., Stahl F., Klinga-Levan K., Kindblom L.G., Mandahl N., Jansson J.O., Levan G., 1999
Amplification and overexpression of the hepatocyte growth factor receptor (HGFR/MET) in rat DMBA sarcomas.
Oncogene. 18: 3226-3234.

Hengartner M.O., 2000
The biochemistry of apoptosis.
Nature. 407: 770-776.

Hernandez L., Pinyol M., Hernadez S., Bea S., Pulford K., Rosenwald A., Lamant L., Falini B., Ott G., Mason D.Y., Delsol G., and Campo E., 1999
TRK-Fused Gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.
Blood. 94: 3265-3268.

Hiebert S.W., Sun W., Davis N., Golub T., Shurtleff S., Buijs A., Downing JR., Grosveld G., Roussel M.F., Gilliland D.G., Lenny N., Meyers S., 1996
The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.
Mol. Cell. Biol. 16: 1349-1355.

Hiebert S.W., Lutterbach B., Amann J., 2001
Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21) and inv(16) fusion proteins.
Cur. Op. Hematol. 8: 197-200.

Hinton H.J., Welham M.J., 1999
Cytokine-induced protein kinase B activation and Bad phosphorylation do not correlate with cell survival of hematopoietic cells.
J. Immunology. 162: 7002-7009.

Ho J.M.Y., Beattie B.K., Squire J.A., Frank D.A., Barber D.L., 1999
Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling.
Blood. 93: 4354-4364.

Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., Luo Y., Pasini B., Höppener J.W.M., van Amstel H.K.P., Romeo G., Lips C.J.M., Buys C.H.C.M., 1994
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
Nature. 367: 375-376.

Holgado- Madruga M., Emlet D.R., Moscatello D.K., Godwin A.K., Wong A.J., 1996
Nature. 379: 560-564.

Holliday R., 1989
Chromosome error propagation and cancer.
Trends Genet. 5: 42-45.

Honda H., Oda H., Suzuki T., Takahashi T., Witte O.N., Ozawa K., Ishikawa T., Yazaki Y., Hirai H., 1998
Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
Blood. 91: 2067-2075.

Hosoi H., Dilling M.B., Shikata T., Liu L.N., Shu L., Ashmun R.A., 1999
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-dependent apoptosis in human rhabdomyosarcoma cells.
Cancer Res. 59: 886-894.

Huang J., Mohammadi M., Rodrigues G.A., Schlessinger J., 1995
Reduced activation of RAF-1 and MAP Kinase by a fibroblast growth factor receptor mutant deficient in stimulation of phosphatidylinositol hydrolysis.
J. Biol. Chem. 270: 5065-5072.

Hubbard S.R., Mohammadi M., Schlessinger J., 1998
Autoregulatory mechanisms in protein-tyrosine kinases.
J. Biol. Chem. 273: 11987-11990.

Hubbard S.R., Till J.H., 2000
Protein tyrosine kinase stucture and function.
Annu. Rev. Biochem. 69: 373-398.

Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G., 2000
Reversibility of acute B-cell leukaemia induced by BCR-ABL1.
Nature Genet. 24: 57-60.

I

Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M.,Mohammadi M., 2001
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
Proc. Natl. Acad. Sci. USA. 98: 7182-7187.

Ilaria R.L., Van Etten R.A., 1996
P210 and P190 BCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members.
J. Biol. Chem. 271: 31704-31710.

Inhorn R.C., Aster J.C., Roach S.A., Slapak C.A., Soiffer R., Tantravahi R., Stone R.M., 1995
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Blood. 85: 1881-1887.

Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Teresa A., Neri M., Neri A., 2001
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).
British J. Haematol. 114: 362-364.

Ito T., Deng X., Carr B., May W.S., 1997
Bcl-2 phosphorylation required for anti-apoptosis function.
J. Biol. Chem. 272: 11671-11673.

Iwata T., Li C.L., Deng C.X., Francomano C.A., 2001
Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice
Hum. Mol. Genet. 10: 1255-1264.

J

Jaakkola S., Salmikangas P., Nylund S., Partanen J., Armstrong E., Pyrhonen S., Lehtovirta P., Nevanlinna H., 1993
Amplification of fgfr4 gene in human breast and gynecological cancers.
Int. J. Cancer. 54: 378-382.

Jang J.H., Shin K.H., Park J.G., 2001
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.
Cancer Res. 61: 3541-3543.

Jaye M., Schlessinger J., Dionne CA., 1992
Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction.
Biochim. Biophys. Acta. 1135: 185-199.

Jefferies H.B.J., Fumagalli S., Dennis P.B., Reinhard C., Pearson R.B., Thomas G., 1997
Rapamycin suppresses 5’TOP mRNA translation through inhibition of p70S6K.
EMBO J. 16: 3693-3704.

Jeffers M., Schmidt L., Nakaigawa N., Webb CP., Weirich G., Kishida T., Zbar B., Vande Woude GF., 1997
Activating mutations for the met tyrosine kinase receptor in human cancer.
Proc Natl Acad Sci U S A. 94:11445-11450.

Jeng Y.M., Lin C.Y., Hsu H.C., 2000
Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma.
Cancer Lett. 154: 107-111.

Jhiang S.M., 2000
The RET proto-oncogene in human cancers.
Oncogene. 19: 5590-5597.

Ji Q.S., Winnier G.E., Niswender K.D., Horstman D., Wisdom R., Magnuson M.A., Carpenter G., 1997
Essential role of the tyrosine kinase substrate phospholipase C-γ1 in mammalian growth and development.
Proc. Natl. Acad. Sci. 94: 2999-3003.

Joazeiro C.A., Wing S.S., Huang H., Leverson J.D., Hunter T., Liu Y.C., 1999
The tyrosine kinase negative regulate c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase.
Science. 8: 309-312.

Johnson DE., Lu J., Chen H., Werner S., and Williams LT., 1991
The human fibroblast growth factor genes: a common structural arrangement underlies the mechanism for generating receptor forms that differ in their third immunoglobulin domain.
Mol. Cell. Biol. 12: 82-88.

Johnson DE., and Williams LT., 1993
Structural and functionnal diversity in the FGF receptor multigene family.
Adv. Cancer Res. 60: 1-41.

Jotterand Bellomo M., Muhlematter D., Wicht M., Delacretaz F., Schmidt P.M., 1992
t(8;9)(p11;q32) in atypical chronic myeloid leukaemia: a new cytogenetic-clinicopathologic association ?
Br. J. Haematol. 81: 307-308.

Jousset C., Carron C., Boureux A., Tran Quang C., Oury C., Dusanter-Fourt I., Charon M., Levin J., Bernard O., Ghysdael J., 1997
A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRβ oncoprotein.
EMBO J. 16: 69-82.

K

Kahan C., Seuwen K., Meloche S., Pouysségur J., 1992
Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts.
J. Biol. Chem. 267: 13369-13375.

Kakizuka A., Miller W.H., Umesono K., Warrell R.P., Frankel S.R., Murty W., Dmitrovsky E., Evans R.M., 1991
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARa with a novel putative transcription factor, PML.
Cell. 66: 663-674.

Kamps M.P., Murre C., Sun XH., Baltimore D., 1990
A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL.
Cell. 60: 547- 555.

Kamps MP., Wright DD., Lu Q., 1996
DNA-binding by oncoprotein E2A-Pbx1 is important for blocking differenciation but dispensable for fibroblast transformation.
Oncogene. 12: 19-30.

Kanda S., Hodgkin M.N., Woodfield R.J., Wakelam M.J.O., Thomas G., Claesson-Welsh L., 1997
Phosphatidylinositol 3’-kinase-independent p70 S6 kinase activation by fibroblast growth factor receptor-1is important for proliferation but not differentiation of endothelial cells.
J. Biol. Chem. 272: 23347-23353.

Kane L.P., Shapiro V.S., Stokoe D., Weiss A., 1999
Induction of NF-κB by the Akt/PKB kinase
Curr. Biol. 9: 601-604.

Kannan K., Givol D., 2000
FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models.
IUBMB Life. 49: 197-205.

Kantarjian H.M., Talpaz M., Dhingra K., Estey E., Keating M.J., Ku S., Trujillo J., Huh Y., Stass S., Kurzrock R., 1991
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.
Blood. 78: 2411-2418.

Karin M., 1999
How NF-kB is activated: the role of the IκB kinase (IKK) complex.
Oncogene. 18: 6867-6874.

Kasper L.H., Brindle PK., Schnabel C.A., Pritchard C.E., Cleary ML., Van Deursen JM., 1999
CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity.
Mol. Cell. Biol. 19: 764-776.

Kassis J., Moellinger J., Lo H., Greenberg N.M., Kim H.G., Wells A., 1999
A role for phospholipase C-γ-mediated signaling in tumor cell invasion.
Clin. Cancer Res. 5: 2251-2260.

Kaufmann S.H., Gores G.J., 2000
Apoptosis in cancer: cause and cure.
BioEssays. 22: 1007-1017.

Kelekar A., Chang B.S., Harlan J.E., Fesik S.W., Thompson C.B., 1997
Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL.
Mol. Cell. Biol. 17: 7040-7046.

Kennedy S.G., Kandel E.S., Cross T.K., Hay N., 1999
Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria.
Mol. Cell. Biol. 19: 5800-5810.

Kim I., Moon S.O., Yu KH., Kim UH., Young Koh G., 2001
A novel fibroblast growth factor receptor-5 preferentially expressed in the pancreas.
Bioch. Biophy. Acta. 1518: 152-156.

Kitabayashi I., Aikawa Y., Yokoyama A., Hosoda F., Nagai M., Kakazu N., Abe T., Ohki M., 2001
Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation.
Leukemia. 15: 89-94.

Klagsbrun M., Baird A., 1991
A dual receptor system is required for basic fibroblast growth factor activity.
Cell. 67: 229-231.

Klint P., Kanda S., Claesson-Welsh L., 1995
Shc and a novel 89-kDa component couple to the Grb2-Sos complex in fibroblast growth factor-2- stimulated cells.
J. Biol. Chem. 270: 23337-23344.

Klint P., and Claesson-Welsh L., 1999
Signal transduction by fibroblast growth factor receptor.
Frontiers in Bioscience. 4: 165-177.

Knezevich S.R., McFadden D.E., Tao W., Lim J.F., and Sorensen P.H.B., 1998
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
Nat. Genet. 18: 184-187.

Knudson A.G., 2001
Two genetic hits (more or less) to cancer.
Nature. 1: 157-162.

Koenigsmann M., Griffin J.D., DiCarlo J., and Cannistra S.A., 1992
Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I.
Blood. 79: 657-665.

Kohler M., Bauknecht T., Grimm M., Birmelin G., Kommoss F., Wagner E., 1992
Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas.
Eur. J. Cancer. 28A: 1432-1437.

Kolch W., Heidecker G., Kochs G., Hummel R., Vahidi H., Mischak H., Finkenzeller G., Marmé D., Rapp U.R., 1993
Protein kinase Cα activates RAF-1 by direct phosphorylation.
Nature. 364: 249-252.

Kouhara H., Hadari YR., Spivak-Kroizman T., Schilling J., Bar-Sagi D., Lax I., Schlessinger J., 1997
A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway.
Cell. 89: 693-702.

Kroon E., Thorsteinsdottir U., Mayotte N., Nakamura T., Sauvageau G., 2001
NUP98-HOXA9 expression in hemopoieic stem cells induces chronic and acute myeloid leukemias in mice.
EMBO J. 20: 350-361.

Kuefer M.U., Look T., Pulford K., Behm F.G., Pattengale P.K., Mason D.Y., Morris S.W., 1997
Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignacy in mice.
Blood. 90: 2901-2910.

Kulkarni S., Reiter A., Smedley D., Goldman J.M., Cross N.C.P., 1999
The genomic structure of ZNF198 and location of breakpoints in the t(8;13) myeloproliferative syndrome.
Genomics. 55: 118-121.

Kuno Y., Abe A., Emi N., Lida M., Yokozawa T., Towatari M., Tanimoto M., and Saito H., 2001
Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12).
Blood. 97:1050-1055.

Kurzrock R., Shtalrid M., Talpaz M., Kloetzer W.S., Gutterman J.U., 1987
Expression of c-abl in Philadelphia-positive acute myelogenous leukemia.
Blood. 70: 1584-1588.

Kuwabara T., Warashina M., Tanabe T., Tani K., Asano S., Taira K., 1998
A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo.
Mol. Cell. 2: 617-627.

L

Lacronique V., Boureux A., Valle V. D., Poirel H., Quang C.T., Mauchauffé M., Berthou C., Lessard M., Berger R., Ghysdael J., and Bernard O. A., 1997
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia.
Science. 278: 1309-1312.

Lacronique V., Boureux A., Monni R., Dumon S., Mauchauffé M., Mayeux P., Gouilleux F., Berger R., Gisselbrecht S., Ghysdael J., and Bernard O. A., 2000
Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.
Blood. 95: 2076-2083.

Larsson H., Klint P., Landgren E., Claesson-Welsh L., 1999
Fibroblast growth factor receptor-1 mediated endothelial cell proliferation is dependent on the src homology (SH)2/SH3 domain-containing adaptor protein Crk.
J. Biol. Chem. 274: 25726-25734.

Lengauer C., Kinzler K.W., Vogelstein B., 1998
Genetic instabilities in human cancers.
Nature. 396: 643-649.

Leslie J., Barker T., Glancy M., Jennings B., Pearson J., 1994
t(8;13)(p11;q12) translocation in a myeloproliferative disorder associated with a T-cell non-Hodgkin lymphoma.
British J. Haematol. 86: 876-878.

Leuenberger H.G.W., Kunstyr I., 1976
Gerontological data of C57BL/6J mice. II. Changes in blood cell counts in the course of natural aging.
J. Gerontol. 31: 648-653.

Lewis J.P., Jenks H., Lazerson J., 1983
Philadelphia chromosome-negative chronic myelogenous leukaemia in a child with t(8;9)(p11or 12q34).
Am. J. Pediatric Hematology/Oncology. 5: 265-269.

Lewis J.P., Welborn J.L., Meyers F.J., Levy N.B., Roschak T., 1987
Mast cell disease followed by leukemia with clonal evolution.
Leukemia Res. 11: 769-773.

Lewis I.D., McDiarmid L.A., Samels L.M., To L.B., Hughes T.P., 1998
Establishment of a reproductible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells.
Blood. 91: 630-640.

Li S., Ilaria R.L., Million R.P., Daley G.Q., Van Etten R.A., 1999a
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
J. Exp. Med. 189: 1399-1412.

Li C., Chen L., Iwata T., Kitagawa M., Fu X.Y., Deng C.X., 1999b
A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
Hum. Mol. Genet. 8: 35-44.

Liang J., Prouty L., Williams B.J., Dayton M.A., Blanchard K.L., 1998
Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2.
Blood. 92: 2118-2122.

Lijima Y., Ito T., Oikawa T., Eguchi M., Eguchi-Ishimae M., Kamada N., Kishi K., Asano S., Sakaki Y., and Sato Y., 2000
A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation.
Blood. 95: 2126-2131.

Liu Q., Schwaller J., Kutok J., Cain D., Aster JC., Williams IR., and Gilliland DG., 2000
Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia.
EMBO J. 19: 1827-1838.

Lockshin R.A., Zakeri Z., 2001
Programmed cell death and apoptosis: origins of the theory.
Nature Mol. Cell. Biol. 2: 545-556.

Longley BJ., Metcalfe DD., Tharp M., Wang X., Tyrrell L., Lu SZ., Heitjan D., Ma Y., 1999
Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.
Proc. Natl. Acad. Sci. 96: 1609-1614.

Look T., 1997
Oncogenic transcription factors in the human acute leukemias.
Science. 278: 1059-1064.

Lowenstein EJ., Daly RJ., Batzer AG., Li W., Margolis B., Lammers R., Ullrich A., Skolnik E.Y., Bar-Sagi D., Schlessinger J., 1992
The SH2 and SH3 domain- containing protein GRB2 links receptor tyrosine kinases to ras signalling.
Cell. 70: 431-442.

Lu Y., Lin Y.Z., LaPushin R., Cuevas B., Fang X., Yu S.X., Davies M.A., Khan H., Furui T., Mao M., Zinner R., Hung M.C., Steck P., Siminovitch K., Mills G.B., 1999
The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells.
Oncogene 18: 7034-7045.

Lugo T.G., Pendergast A.N., Muller A.J., Witte O.N., 1990
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Science. 247: 1079-1082.

Lui V.W.Y, He Y., Goyal K., Huang L., 2001
Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma.
Mol. Ther. 3: 169-177.

M

Macdonald D., Aguiar RCT., Mason PJ., Goldman J.M., and Cross NCP., 1995
A new myeloproliferative disorder associated with chromosomal translocations involving 8p11 : a review.
Leukemia. 9: 1628-1630.

Mahgoub N., Taylor B.R., Gratiot M., Kohl N.E., Gibbs J.B., Jacks T., Shannon K.M., 1999
In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.
Blood. 94: 2469-2476.

Majewski M., Nieborowska-Skorska M., Salomoni P., Slupianek A., Reiss K., Trotta R., Calabretta B., Skorski T., 1999
Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt.
Cancer Res. 59: 2815-2819.

Makin G., Dive C., 2001
Apoptosis and cancer chemotherapy.
Trends Cell Biol. 11: S22-S26.

Malbrain M.L.N.G., Van den Bergh H., Zachée P., 1996
Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: a complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality.
Br. J. Haematol. 92:176-183.

Markowitz D., Goff S., Bank A., 1988
A safe packaging line for gene transfer: separating viral genes on two different plasmids.
J. Virol. 62: 1120-1124.

Markowitz D., Hesdorffer C., Ward M., Goff S., Bank A., 1990
Retroviral gene transfer using safe and efficient packaging cell lines.
Ann. NY. Acad. Sci. 612: 407-414.

Martiat P., Mecucci C., Nizet Y., Stul M., Philippe M., Cassiman J.J., Michaux J.L., Van den Berghe H., Sokal G., 1990
P190 BCR/ABL transcript in a case of Philadelphia-positive multiple myeloma.
Leukemia. 4: 751-754.

Martin D.B., Nelson P.S., 2001
From genomics to proteomics: techniques and applications in cancer research.
Trends in Cell Biol. 11: S60-S65.

Martinez-Climent J.A., Vizcarra E., Benet I., Marugan I., Terol M.J., Solano C., Arbona C., Tormo M., Comes A.M., Garcia-Conde., 1998
Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12).
Leukemia. 12: 999-1000.

Maru Y., 2001
Molecular biology of chronic myeloid leukemia.
Int. J. Hematol. 73: 308-322.

Mayer B.J., Hamaguchi M., Hanafusa H., 1988
A novel viral oncogene with structural similarity to phospholipase C.
Nature. 332: 272-275.

McWhirter J.R., Galasso D.L., and Wang J.Y., 1993
A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
Mol. Cell. Biol. 13: 7587-7595.

Meeker T.C., Hardy D., Willman C., Hogan T., and Abrams J., 1990
Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia.
Blood. 76: 285-289.

Melo J.V., Myint H., Galton D.A., Goldman J.M., 1994
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia ?
Leukemia 8: 1795-1796.

Melo J.V., 1996
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
Blood. 88: 2375-2384.

Meyers S., Noel L., Hiebert SW., 1995
The t(8;21) fusion protein interferes with AML1B dependent transcriptional activation.
Mol. Cell. Biol. 15: 1974-1982.

Meyers G.A., Day D., Goldberg R., Daentl D.L., Przylepa K.A., Abrams L.J., Graham J.M., Feingold M., Moeschler J.B., Rawnsley E., Scott A.F., Jabs E.W., 1996
FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing.
Am. J. Hum. Genet. 58: 491-498.

Michaux L., Mecucci C., Velloso E.R.P., Dierlamm J., Criel A., Louwagie A., Van Orshoven A.V., Van den Berghe H., 1996
About the t(8;13)(p11;q12) clinico-pathologic entity.
Blood. 87: 1658-1659.

Migliaccio E., Mele S., Salcini A.E., Pelicci G., Lai K., Superti F.G., Pawson T., Di F.P., Lanfrancone L., Pelicci P.G., 1997
Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase –fos signalling pathway.
EMBO J. 16: 706-716.

Miki T., Fleming T.P., Bottaro D.P., Rubin J.S., Ron D., Aaronson S.A., 1991
Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop.
Science. 251: 72-75.

Million R.P., Van Etten R.A., 2000
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
Blood. 96: 664-670.

Mitani K., Sato Y., Tojo A., Ishikawa F., Kobayashi Y., Miura Y., Miyazono K., Urabe A. Takaku F., 1990
Philadelphia chromosome positive B-cell type malignant lymphoma expressing an aberrant 190 kDa BCR-ABL protein.
British J. Haematol. 76: 221-225.

Mitani K., Ogawa S., Tanaka T., Miyoshi H., Kurokawa MK., Mano H., Yazaki Y., Ohki M., Hirai H., 1994
Generation of the AML1-EVi-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
EMBO J. 13: 504-510.

Mitelman F., Johansson B., Mertens F., 2001
Mitelman database of chromosome aberrations in cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman

Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y., Kamada N., Ohki M., 1993
The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript.
EMBO J. 12: 2715-2721.

Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W., Dionne C.A., Jaye M., Rubinstein M., and Schlessinger J., 1991
A Tyrosine-Phosphorylated Carboxy-Terminal Peptide of the Fibroblast Growth factor Receptor (Flg) Is a Binding Site for the SH2 Domain of Phospholipase C-γ1.
Mol.Cell.Biol. 11: 5068-5078.

Mohammadi M., Dionne A., Li W., Li N., Spivak T., Honegger A. M., Jaye M., and Schlessinger J., 1992
Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis.
Nature. 358: 681-684.

Mohammadi M., Dikic I., Sorokin A., Burgess WH., Jaye M., and Schlessinger J., 1996a
Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction.
Mol. Cell. Biol. 16: 977-989.

Mohammadi M., Schlessinger J. Hubbard R., 1996b
Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism.
Cell 86: 577-587.

Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard R., and Schlessinger J., 1997
Structures of tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.
Science. 246: 955-960.

Monica K., LeBrun DP., Dedera DA., Brown R., Cleary ML., 1994
Transformation properties of the E2a-Pbx1 chimeric oncoprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable.
Mol Cell Biol 14: 8304-8314.

Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A., 2000
The transmembrane mutation G380R in Fibroblast Growth factor Receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
Mol. Cell. Biol. 20: 516-522.

Moritz T., Dutt P., Xiao X., Carstanjen D., Vik T., Hanenberg H., Williams D.A., 1996
Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments.
Blood. 88: 855-862.

Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., and Look T., 1994
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hodgkin’s lymphoma.
Science. 263: 1281-1284.

Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., Biegel J.A., Hayes R.L., Wong A.J., 1995
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.
Cancer Res. 55: 5536-5539.

Muenke M., Schell U., Hehr A., Robin NH., Losken W., Schinzel A., Pulleyn LJ., Rutland P., Reardon W., Malcom S., Winter RM., 1994
A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome.
Nature Genet. 8: 269-274.

Mugneret F., Chaffanet M., Maynadie M., Guasch G., Favre B., Casasnovas O., Birnbaum B., Pébusque M-J., 2000
The 8p12 Myeloproliferative disorder : t(8;19)(p12;q11.3), a novel translocation involving the FGFR1 gene.
British J. Of Haematology. 110: 1-4.

Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E., Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A., Telenius H., Tunnacliffe A., Ponder B.A.J., 1993
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
Nature. 363: 458-460.

Mulligan L.M., Eng C., Healey C.S., Clayton D., Kwok J.B.J., Gardner E., Ponder M.A., Frilling A., Jackson C.E., Lehnert H., Neumann H.P.H., Thibodeau S.N., Ponder B.A.J., 1994
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
Nature Genet. 6: 70-74.

Murakami H., Iwashita T., Asai N., Shimono Y., Iwata Y., Kawai K., Takahashi M., 1999
Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation
Biochem. Biophys. Res. Commun. 262: 68-75.

N

Naeem R., Singer S., Fletcher J.A., 1995
Translocation t(8;13)(p11;q11-12) in stem cell leukemia/lymphoma of T-cell and myeloid lineages.
Genes Chrom. Cancer. 12: 148-151.

Nakayama H., Inamitsu., Ohga S., Kai T., Suda M., Matsuzaki A., Ueda K., 1996
Chronic myelomonocytic leukaemia with t(8;9)(p11;q34) in childhood: an example of the 8p11 myeloproliferative disorder ?
British. J. Haematol. 92: 692-695.

Nagata H., Worobec A.S., Semere T., Metcalfe D.D., 1998
Elevated expression of the proto-oncogene c-kit in patients with mastocytosis.
Leukemia. 12: 175-181.

Naski MC., Wang Q., Xu J., Ornitz DM., 1996
Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Nature genet. 13: 233-237.

Neilson K.M., Friesel R., 1996
Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains.
J. Biol. Chem. 271: 25049-25057.

Neshat M.S., Raitano A.B., Wang H.G., Reed J.C., Sawyers C.L., 2000
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and –independent pathways: roles for phosphatidylinositol 3-kinase and raf.
Mol. Cell. Biol. 20: 1179-1186.

Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L., 2001
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Proc. Natl. Acad. Sci. 28: 10314-10319.

Newton A.C., 1995
Protein kinase C: structure, function, and regulation.
J. Biol. Chem. 270: 28495-28498.

Nguyen M.H.H., Ho J.M.Y., Beattie B.K., Barber D.L., 2001
TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3’-kinase/protein kinase B signaling pathway.
J. Biol. Chem. 276: 32704-32713.

Nieborowska-Skorska M., Wasik M.A., Slupianek A., Salomoni P., Kitamura T., Calabretta B., Skorski T., 1999
Signal transducer and activator of transcription (STAT)5 activation by BCR-ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
J. Exp. Med. 189: 1229-1242.

Nieborowska-Skorska M., Slupianek A., Xue L., Zhang Q., Raghunath P.N., Hoser G., Wasik M.A., Morris S.W., Skorski T., 2001
Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Cancer Res. 61: 6517-6523.

Nosaka T., Kawashima T., Misawa K., Ikuta K., Mui A.L.F., Kitamura T., 1999
STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells.
EMBO J. 18: 4754-4765.

Nowell P., Hungerford D., 1960
Chromosomes of normal and leukemic human leucocytes.
J. Natl. Cancer Inst. 25: 85.

Nucifora G., Rowley JD., 1995
AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.
Blood. 86: 1-14.

O

Okazuka K., Toba K., Kawai K., Nikkuni K., Tsuchiyama J., Momoi A., Kanazawa N., Nagai K., Suzuki N., Aizawa Y., 2001
Extramedullary T lymphoid blast crisis representing an additional translocation, t(6;8)(q25;q22) in a patient with Philadelphia-positive chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Leukemia Research. 25: 1089-1094.

Okuda K., Golub T.R., Gilliland D.G., Griffin J.D., 1996
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Oncogene. 13: 1147-1152.

Oldridge M., Wilkie A.O., Slaney S.F., Poole M.D., Pulleyn L.J., Rutland P., Hockley A.D., Wake M.J., Goldin J.H., Winter R.M., Reardon W., Malcolm S., 1995
Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome.
Hum. Mol. Genet. 4: 1077-1082.

O’Neill T.J., Craparo A., Gustafson TA., 1994
Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two hybrid system.
Mol. Cell. Biol. 14: 6433-6442.

Onichtchouk D., Chen YG., Dosch R., Gawantka V., Delius H., Massagué J., Niehrs C., 1999
Silencing of TGFβ signalling by the pseudoreceptor BAMBI.
Nature. 401: 480-485.

Ong SH., Guy GR., Hadari YR., Laks S., Gotoh N., Schlessinger J. Lax I., 2000
FRS2 proteins recruit intracellular signalling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors.
Mol. Cell. Biol. 20: 979-989.

Ong SH., Hadari YR., Gotoh N., Guy GR., Schlessinger J. Lax I., 2001
Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins.
Proc. Natl. Acad. Sci. 98: 6074-6079.

Ornitz D.M., Leder P., 1992
Ligand specificity and heparin dependence of fibroblast growth factor receptor 1 and 3.
J. Biol. chem. 267: 16305-16311.

Ornitz D.M., Itoh N., 2001
Fibroblast growth factors.
Genome Biol. 2: S3005.

Oscier D.G., Gardiner A., Dyer M., 1993
t(8;9) in chronic myeloid leukaemia.
Br. J. Haematol. 83: 176-177.

Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B., 1999
NF-κB activation by tumor necrosis factor requires the Akt serine-threonine kinase.
Nature. 401: 82-85.

P

Pandolfi P.P., 2001
In vivo analysis of the molecular genetics of acute promyelocytic leukemia.
Oncogene. 20: 5726-5735.

Pane F., Frigeri F., Sindona M., Luciano L., Ferrara F., Cimino R., Meloni G., Saglio G., Salvatore F., Rotoli B., 1996
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction).
Blood. 88: 2410-2414.

Panek R.L., Lu G.H., Dahring T.K., Batley B.L., Connolly C., Hamby J.M., and Brown K.J., 1998
In Vitro Biological Characterization and Antiangiogenic effects od PD 166866, a selective Inhibitor of the FGF-1 Receptor Tyrosine Kinase.
J. of Pharmac. and Exp. Therap. 286: 569-577.

Pang L., Sawada T., Decker S.J., Saltiel A.R., 1995
Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor.
J. Biol. Chem. 270: 13585-13588.

Park W.J., Meyers G.A., Li X., Theda C., Day D., Orlow S.J., Jones M.C., Jabs E.W., 1995
Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability.
Hum. Mol. Genet. 4: 1229-1233.

Pawson T., Scott J.D., 1997
Signaling through scaffold, anchoring, and adaptor proteins.
Science. 278: 2075-2080.

Pawson T., Nash P., 2000
Protein-protein interactions define specificity in signal transduction.
Genes & Dev.. 14: 1027-1047.

Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., Pendergast A.M., Bronson R., Aster J.C., Scott M.L., Baltimore D., 1998
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving p210 bcr/abl-transduced bone marrow.
Blood. 92: 3780-3792.

Pearson R.B., Dennis P.B., Han J.W., Williamson N.A., Kozma S.C., Wettenhall R.E., Thomas G., 1995
The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain.
EMBO J. 14: 5279-5287.

Pébusque M.J., Chaffanet M., Popovici C., Birnbaum D., 2000
FGFR1 et MOZ, deux gènes clés dans les hémopathies malignes associées à des réarrangements de la région chromosomique 8p11-12.
Bull. Cancer. 87: 887-894.

Peles E., Ben Levy R., Or E., Ullrich A., Yarden Y., 1991
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase Cγ.
EMBO J. 10: 2077-2086.

Pelicci G., Lanfrancone L., Grignani F., McGlade J., Cavallo F., Forni G., Nicoletti I., Grignani F., Pawson T., Pelicci P.G., 1992
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction.
Cell. 70: 93-104.

Penault-Llorca F., Bertucci F., Adélaïde J., Parc P., Coulier F., Jacquemier J., Birnbaum D., deLapeyriere O., 1995
Expression of FGF and FGF receptor genes in human breast cancer.
Int. J. Cancer. 61: 170-176.

Peters K.G., Marie J., Wilson E., Ives H. E., Escobedo J., Rosario M. D., Mirda D., and Williams L.T., 1992
Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis.
Nature. 358: 678-681.

Peters D.G., Hoover R.R., Gerlach M.J., Koh E.Y., Zhang H., Choe K., Kirschmeier P., Bishop R., Daley G.Q., 2001
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Blood. 97: 1404-1412.

Plotnikov A.N., Schlessinger J., Hubbard SR., Mohammadi M., 1999
Structural basis for FGF receptor dimerization and activation.
Cell. 98: 641-650.

Plotnikov A.N., Hubbard SR., Schlessinger J., Mohammadi M., 2000
Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.
Cell. 101: 413-424.

Plowright E.E., Li Z., Bergsagel P.L., Chesi M., Barber D.L., Branch D.R., Hawley R.G., Stewart A.K., 2000
Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
Blood. 95: 992-998.

Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., Frost P., Dreisbach V., Blenis J., Gaciong Z., Fisher P., Sawyers C., Hedrick-Ellenson L., Parsons R., 2001
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
Proc. Natl. Acad. Sci. 98: 10320-10325.

Pollock J.L., Westervelt P., Kurichety A.K., Pelicci P.G., Grisolano J.L., Ley T.J., 1999
A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia.
Proc. Natl. Acad. Sci. 96: 15103-15108.

Ponder B.A.J., 2001
Cancer genetics.
Nature. 411: 336-341.

Popovici C., Adélaïde J., Ollendorff V., Chaffanet M., Guasch G., Jacrot M., Leroux D., Birnbaum D., Pébusque M-J., 1998
Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)(p12;q12).
Proc. Natl. Acad. Sci. USA. 95: 5712-5717.

Popovici C., Ollendorff V., Coulier F., Pébusque M-J., Birnbaum D., 1998
Les FGF et leurs récepteurs dans l’hématopoïèse normale et pathologique.
Hématologie. 4: 361-369.

Popovici C., Zhang B., Grégoire M-J., Jonveaux P., Pochitaloff M., Birnbaum D., Pébusque M-J., 1999
The t(6;8)(q27;p11) Translocation in a Stem Cell Myeloproliferative Disorder Fuses a Novel Gene, FOP, to Fibroblast Growth Factor Receptor 1.
Blood 93: 1381-1389.

Porter A.C., Vaillancourt R.R., 1998
Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.
Oncogene. 16: 1343-1352.

Pulford K., Morris S.W., Mason D.Y., 2001
Anaplastic lymphoma kinase proteins and malignancy.
Curr. Op. Hematol. 81: 231-236.

R

Raanani P., Segal E., Levi I.I., Bercowicz M., Berkenstat H., Avigdor A., Perel A., Ben-Bassat I.I., 2000
Diffuse Alveolar hemorrhage in acute promyelocytic leukemia patients treated with Atra- a manifestation of basic disease or the treatment.
Leukemia Lymphoma. 37: 605-610.

Rabbitts T.H., 2001
Chromosomal translocation master genes, mouse models and experimental therapeutics.
Oncogene. 20: 5763-5777.

Rabin S.J., Cleghon V., Kaplan D.R., 1993
SNT, a differentiation-specific target of neurotrophic factor-induced tyrosine kinase activity in neurons and PC12 cells.
Mol. Cell. Biol. 13: 2203-2213.

Raffioni S., Thomas D., Foehr E.D., Thompson L.M., Bradshaw R.A., 1999
Comparison of the intracellular signaling responses by three chimeric fibroblast growth factor receptors in PC12 cells.
Proc. Natl. Acad. Sci. 96: 7178-7183.

Ramaswamy S., Nakamura N., Vazquez F., Batt D.B., Perera S., Roberts T.M., Sellers W.R., 1999
Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Proc. Natl. Acad. Sci. 96: 2110-2115.

Rameh L.E., Rhee S.G., Spokes K., Kazlauskas A., Cantley L.C., Cantley L.G., 1998
Phosphoinositide 3-kinase regulates phospholipase Cγ-mediated calcium signaling.
J. Biol. Chem. 273: 23750-23757.

Rao P.H., Cesarman G., Coleman M., Verma R.S., 1992
Cytogenetic evidence for extramedullary blast crisis with t(8;13)(q11;p11) in chronic myelomonocytic leukemia.
Acta Haematol. 88: 201-203.

Ravichandran K.S., 2001
Signaling via Shc family adapter proteins.
Oncogene. 20: 6322-6330.

Redner R.L., Rush E.A., Faas S., Rudert W.A., Corey S.J., 1996
The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin retinoic acid receptor fusion.
Blood. 87: 882-886.

Reed J.C., 1995
Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance.
Cur. Op. Oncol. 7: 541-546.

Reed J.C., 2001
Apoptosis-regulating proteins as targets for drug discovery.
Trends Mol. Med. 7: 314-319.

Reich A., Sapir A., Shilo B.Z., 1999
Sprouty is a general inhibitor of receptor tyrosine kinase signaling.
Development. 126: 4139-4147.

Reifsnyder C., Lowell J., Clarke A., Pillus L., 1996
Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases.
Nature Genet. 14: 42-49.

Reiter A., Sohal J., Kulkarni S., Chase A., MacDonald D.H., Aguiar R.C., Goncalves C., Hernandez J.M., Jennings B.A., Goldman J.M., Cross N.C., 1998
Consistent fusion of ZNF198 to the fibroblast growth factor receptor –1 in the t(8;13)(p11;q12) myeloproliferative syndrome.
Blood. 92: 1735-1742.

Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S., 1998
A requirement for NF-κB activation in Bcr-Abl mediated transformation.
Genes Dev. 12: 968-981.

Reuther G.W., Lambert Q.T., Caligiuri M.A., Der C.J, 2000
Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia.
Mol. Cell. Biol. 20: 8655-8666.

Richelda R., Ronchetti D., Baldini L., Cro L., Viggiano L., Marzella R., Rocchi M., Otsuki T., Lombardi L., Maiolo A.T., Neri A., 1997
A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.
Blood. 90: 4062-4070.

Ritchie K.A., Aprikyan A.A.G., Bowen-Pope D.F., Norby-Slycord C.J., Conyers S., Sitnicka E., Bartelmez S.H., Hitckstein D.D., 1999
The Tel-PDGFRβ fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.
Leukemia. 13: 1790-1803.

Robertson SC., Tynan JA., Donoghue DJ., 2000
RTK mutations and human syndromes.
Trends In Genet. 16: 265-271.

Rodrigues G.A., Park M., 1994
Oncogenic activation of tyrosine kinases.
Curr. Op. in Genet. & Dev. 4: 15-24.

Rodrigues GA., Falasca M., Zhang Z., Ong SH., Schlessinger J., 2000
A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling.
Mol. Cell. Biol. 20: 1448-1459.

Romana S.P., Mauchauffe M., Le Coniat M., Chumakov I., Le Paslier D., Berger R., Bernard O.A., 1995
The t(12;21) of acute lymphoblastic leukemia results in a Tel-AML1 gene fusion.
Blood. 85: 3662-3670.

Romashkova J.A., Makarov S.S., 1999
NF-κB is a target of AKT in anti-apoptotic PDGF signalling.
Nature. 401: 86-90.

Ronchetti D., Greco A., Compasso S., Colombo G., Dell’Era P., Otsuki T., Lombardi L., Neri A., 2001
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Oncogene. 20: 3553-3562.

Ross T.S., Bernard O.A., Berger R., Gilliland D.G., 1998
Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor β receptor (PDGFβR) in chronic myelomonocytic leukemia with t(5;7)(q33; q11.2).
Blood. 91: 4419-4426.

Ross T.S., Gilliland D.G., 1999
Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor β receptor fusion protein.
J. Biol. Chem. 274: 22328-22336.

Roumiantsev S., de Aos I.E., Varticovski L., Ilaria R.L., Van Etten R.A., 2001
The Src homology 2 domain of bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
Blood. 97: 4-13.

Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet JM., Maroteaux P., Le Merrer M., Munnich A., 1994
Mutations in the gene encoding fibroblast growth factor receptor –3 in achondroplasia.
Nature. 371: 252-254.

Rousseau F., el Ghouzzi V., Delezoide A.L., Legeai-Mallet L., Le Merrer M., Munnich A., Bonaventure J., 1996
Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TDI).
Hum. Mol. Genet. 5: 509-512.

Rowley J.D., 1999
The role of chromosome translocations in leukemogenesis.
Sem. in Hematol. 36 (supl. 7): 59-72.

Rutland P., Pulleyn L.J., Reardon W., Baraitser M., Hayward R., Jones B., Malcolm S., Winter R.M., Oldridge M., Slaney S.F., Poole M.D., Wilkie A.O.M., 1995
Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes.
Nature Genet. 9: 173-176.

Ruvolo P.P., Deng X., Carr B.K., May W.S., 1998
A functional role for mitochondrial protein kinase Cα in Bcl2 phosphorylation and suppression of apoptosis.
J. Biol. Chem. 273: 25436-25442.

Ruvolo P.P., Deng X., May W.S., 2001
Phosphorylation of Bcl2 and regulation of apoptosis.
Leukemia. 15: 515-522.

S

Sahni M., Ambrosetti D.C., Mansukhani A., Gertner R., Levy D., Basilico C., 1999
FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway.
Genes Dev. 13: 1361-1366.

Salomon-Nguyen F., Della-Valle V., Mauchauffé M., Busson-Le Coniat M., Ghysdael J., Berger R., and Bernard O., 2000
The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion.
Proc. Natl. Acad. Sc. USA. 97: 6757-6762.

Salomoni P., Condorelli F., Sweeney S.M., Calabretta B., 2000
Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects.
Blood. 96: 676-684.

Sanchez-Garcia I., Martin-Zanca., 1997
Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras.
J. Mol. Biol. 267: 225-228.

Santoro M., Carlomagno F., Romano A., Bottaro D.P., Dathan N.A., Grieco M.,Fusco A., Vecchio G., Matoskova B., Kraus M.H., Di Fiore P.P., 1995
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
Science. 267: 381-383.

Sattler M., Salgia R., 1997
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
Cytok. Growth Factor Rev. 8: 63-79.

Sawyers C.L., Denny C.T., and Witte O.N., 1991
Leukemia and the disruption of normal hematopoiesis.
Cell. 64: 337-350.

Scheid M.P., Duronio V., 1998
Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/Akt: involvement of MEK upstream of Bad phosphorylation.
Proc. Natl. Acad. Sci. 95: 7439-7444.

Schimmer A.D., Hedley D.W., Penn L.Z., Minden M.D., 2001
Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view.
Blood. 98: 3541-3553.

Schlessinger J., 2000a
Cell signaling by receptor tyrosine kinases.
Cell. 103: 211-225.

Schlessinger J., 2000b
New roles of Src kinases in control of cell survival and angiogenesis.
Cell. 100: 293-296.

Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V., Yeh B.K., Yayon A., Linhardt R.J., Mohammadi M., 2000c
Crystal structure of a ternary FGF-FGFR-Heparin complex reveals a dual role for heparin in FGFR binding and dimerization.
Mol. Cell. 6: 743-750.

Schlessinger J., and Ullrich A., 1992
Growth factor signaling by receptor tyrosine kinases.
Neuron. 9: 383-391.

Schmelzle T., Hall M.N., 2000
TOR, a central controller of cell growth.
Cell. 103: 253-262.

Schmidt L., Duh FM., Chen F., Kishida T., Glenn G., Choyke P., Scherer SW., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim UR., Feltis JT., Casadevall C., Zamarron A., Bernues M., Richard S., Lips CJ., Walther MM., Tsui LC., Geil L., Orcutt ML., Stackhouse T., Zbar B., et al., 1997
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
Nat. Genet. 16:68-73.

Schwaller J., Frantsve J., Aster J., Williams I.R., Tomasson M.H., Ross T.S., Peeters P., Van Rompaey L., Van Etten R.A., Ilaria R., Marynen P., Gilliland D.G., 1998
Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.
EMBO J. 17: 5321-5333.

Schwaller J., Parganas E., Wang D., Cain D., Aster J.C., Williams I.R., Lee C.K., Gerthner R., Kitamura T., Frantsve J., Anastasiadou E., Loh M.L., Levy D.E., Ihle J.N., Gilliland D.G., 2000
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2.
Mol. Cell. 6: 693-704.

Ségal-Bendirdjian E., 1999
Mort cellulaire: signalisation et exécution de l’apoptose.
Hématologie. 5: 376-387.

Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M., Abraham R.T., 2000
A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
Cancer Res. 60: 3504-3513.

Sexl V., Piekorz R., Moriggl R., Rohrer J., Brown M.P., Bunting K.D., Rothammer K., Roussel M.F., Ihle J.N., 2000
Stat5a/b contribute to interleukin7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of Stat5.
Blood. 96: 2277-2283.

Shain KH., Landowski TH., and Dalton WS., 2000
The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance.
Curr. opin. in Oncol. 12: 557-563.

Shannon K., 1995
The Ras signaling pathway and the molecular basis of myeloid leukemogenesis.
Curr. Op. In Hematol. 2: 305-308.

Shaoul E., Reich-Slotky R., Berman B., Ron D., 1995
Fibroblast growth factor receptors display both common and distinct signaling pathways.
Oncogene. 10: 1553-1561.

Shiang R., Thompson L.M., Zhu Y.Z., Church D.M., Fielder T.J., Bocian M., Winokur S.T., Wasmuth J.J., 1994
Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.
Cell. 78: 335-342.

Sibley K., Stern P., Knowles M.A., 2001
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumors.
Oncogene. 20: 4416-4418.

Sinclair H., Van der Berg Goldman J.M., and Cross N.C.P., 2000
Identification of four new variant translocations involving FGFR1 in myeloproliferative disorders with a propensity to evolve into AML.
Abstract of the 42nd Annual Meeting of the American Society of Hematology.

Sjöblom T., Boureux A., Rönnstrand L., Heldin C.H., Ghysdael J., Östman A., 1999
Characterization of the chronic myelomonocytic leukemia associated TEL-PDGFβR fusion protein.
Oncogene. 18: 7055-7062.

Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J.K., Trotta R., Wlodarski P., Perrotti D., Chan T.O., Wasik M.A., Tsichlis P.N., Calabretta B., 1997
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
EMBO J. 16: 6151-6161.

Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L., 1987
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235: 177-182.

Sleeman M., Fraser J., McDonald M., Yuan S., White D., Grandison P., Kumble K., Watson J.D., Murison J.G., 2001
Identification of a new fibroblast growth factor receptor, FGFR5.
Gene. 271: 171-182.

Slupianek A., Nieborowska-Skorska M., Hoser G., Morrione A., Majewski M., Xue L., Morris S.W., Wasik M.A., Skorski T., 2001
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Cancer Res. 61: 2194-2199.

Smedley D., Hamoudi R., Clark J., Warren W., Abdul-Rauf M., Somers G., Venter D., Fagan K., Cooper C., Shipley J., 1998
The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 to a novel gene RAMP.
Hum. Mol. Genet. 7: 637-642.

Smedley D., Demiroglu A., Abdul-Rauf M., Heath C., Cooper C., Shipley J., Cross N.C.P., 1999
ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.
Neoplasia. 1: 349-355.

Smith J.M., Mayer B.J., 2002
ABL: mechanisms of regulation and activation.
Frontiers in Bioscience. 7: d31-42.

Soengas M.S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X., McCombie R., Herman J.G., Gerald W.L., Lazebnik Y.A., Cordon-Cardo C., Lowe S.W., 2001
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma.
Nature. 409: 207-211.

Sohal J., Chase A., Mould S., Corcoran M., Oscier D., Wilkins B., Iqbal S., Parker S., Welborn J., Harris R.I., Martinelli G., Montefusco V., Wymann, MP., Pirola L., 1998
Structure and function of phosphoinositide 3-kinases.
Biochim. Biophys. Acta. 1436:127-150.

Sohal J., Chase A ., Iqbal S., Parker S., Goldman J.M., and Cross N.C.P., 1999
Two color FISH to detect FGFR1 rearrangements in myeloproliferative disorders : identification of the t(8;17)(p11;q25) as a new cytogenetic variant.
Blood. 94: 180b.

Sohal J., Chase A., Mould S., Corcoran M., Oscier D., Iqbal S., Parker S., Welborn J., Harris R.I., Martinelli G., Montefusco V., Sinclair P., Wilkins B.S., van den Berg H., Vanstraelen D., Goldman J.M., Cross N.C.P., 2001
Identification of four new translocations involving FGFR1 in myeloid disorders.
Genes Chromosomes Cancer. 32: 155-163.

Somers G.R., Slater H., Rockman S., Ekert H., Southey M.C., Chow C.W., Armes J.E., Venter D.J., 1997
Coexistent T-cell lymphoblastic lymphoma and an atypical myeloproliferative disorder associated with t(8;13)(p21;q14).
Pediatric Pathol. Lab. Med. 17: 141-158.

Songyang Z., Shoelson S.E., Chaudhuri M., Gish G., Pawson T., Haser W.G., King F., Roberts T., Ratnofsky S., Lechleider R.J., Neel BG., Birge R.B., Fajardo J.E., Chou M.M., Hanafusa H., Schaffhausen B., Cantley L.C., 1993
SH2 domains recognize specific phosphopeptide sequences.
Cell. 72: 767-778.

Songyang Z., Baltimore D., Cantley L.C., Kaplan D.R., Franke TF., 1997
Interleukin 3-dependent survival by the Akt protein kinase.
Proc. Natl. Acad. Sci. 94: 11345-11350.

Sorokin A., Mohammadi M., Huang J., Schlessinger J., 1994
Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766.
J. Biol. Chem. 269: 17056-17061.

Sözeri O., Kerstin V., Liyanage M., Frith D., Kour G., Mark III G.E., Stabel S., 1992
Activation of the c-Raf protein kinase by protein kinase C phosphorylation.
Oncogene. 7: 2259-2262.

Spain L.M., Mulligan R.C., 1992
Purification and characterization of retrovirally transduced hematopoietic stem cells.
Proc. Natl. Acad. Sci. 89: 3790-3794.

Spangrude G.J., Smith L., Uchida N., Ikuta K., Heimfeld S., Friedman J., Weissman I.L., 1991
Mouse hematopoietic stem cells.
Blood. 78: 1395-1402.

Spivak-Kroizman T., Lemmon M.A., Dikic I., Ladbury J.E., Pinchasi D., Huang J., Jaye M., Crumley G., Schlessinger J., and Lax I., 1994
Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation and cell proliferation.
Cell. 79: 1015-1024.

Spivak-Kroizman T., Mohammadi M., Hu P., Jaye M., Schlessinger J., and Lax I., 1994b
Point mutation in the fibroblast growth factor receptor eliminates phosphatidylinositol hydrolysis without affecting neuronal differentiation.
J. Biol. Chem. 269: 14419-14423.

Spritz RA., Giebel LB., Holmes SA., 1992
Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism.
Am. J. Hum. Genet. 50: 261-269.

Stam J.C., Geerts W.J.C., Versteeg H.H., Verkleij A.J., van Bergen en Henegouven P.M.P., 2001
The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt.
J. Biol. Chem. 276: 25176-25183.

Stauber D.J., DiGabriele AD., Hendrickson WA., 2000
Structural interactions of fibroblast growth factor receptor with its ligand
Proc. Natl. Acad. Sci. 97: 49-54.

Stehelin D., Varmus H.E., Bishop J.M., Vogt P.K., 1976
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA.
Nature. 260: 170-173.

Stein R.C., and Waterfield M.D., 2000
PI3-kinase inhibition: a target for drug development ?
Mol. Med. Today 6: 347-357.

Sternberg D.W., Tomasson M.H., Carroll M., Curley D.P., Barker G., Caprio M., Wilbanks A., Kazlauskas A., Gilliland D.G., 2001
The TEL-PDGFβR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.
Blood. 98: 3390-3397.

Still I.H., Chernova O., Hurd D., Stone R.M., Cowell J.K., 1997
Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11.
Blood. 90: 3136-3141.

Strissel PS., Strick R., Rowley JD., Zeleznik-Le NJ., 1998
An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site co-localize near exon 9 in the MLL breakpoint cluster region.
Blood. 92: 3793-3803.

Su W.C.S., Kitagawa M., Xue N., Xie B., Garofalo S., Cho J., Deng C., Horton W.A., Fu X.Y., 1997
Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.
Nature. 386: 288-292.

Sun M., Wang G., Paciga J.E., Feldman R.I., Yuan Z.Q., Ma X.L., Shelley S.A., Jove R., Tsichlis P.N., Nicosia S.V., Cheng J.Q., 2001
AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.
Am. J. Pathol. 159: 431-437.

Szeberenyi J., Cai H., and Cooper G.M., 1990
Effect of a dominant inhibitory Ha-ras mutation on neuronal differentiation of PC12 cells.
Mol. Cell. Biol. 10: 5324-5332.

T

Taki T., Sako M., Tsuchida M., Hayashi Y., 1997
The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene.
Blood. 89: 3945-3950.

Tanabe T., Kuwabara T., Warashina M., Tani K., Taira K., Asano S., 2000
Oncogene inactivation in a mouse model.
Nature. 406: 473-474.

Tanaka T., Mitani K., Kurokawa M., Ogawa S., Tanaka K., Nishida J., Yazaki Y., Shibata Y., Hirai H., 1995
Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.
Mol. Cell. Biol. 15: 2383-2392.

Tanaka K., Tanaka T., Kurokawa M., Imai Y., Ogawa S., Mitani K., Yazaki Y., Hirai H., 1998
The AML1/ETO (MTG8) and AML1/EVi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2β (CBFβ) in the nucleus more efficiently than wild type AML1.
Blood. 91: 1688-1699.

Tannheimer S.L., Rehemtulla A., Ethier S.P., 2000
Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE.
Breast Cancer Res. 2: 311-320.

Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.Z., Wilkin DJ., Lachman R.S., Wilcox W.R., Rimoin D.L., Cohn D.H., Wasmuth J.J., 1995a
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.
Nature genet. 9: 321-328.

Tavormina P.L., Rimon D.L., Cohn D.H., Zhu Y.Z., Shiang R., Wasmuth J.J., 1995b
Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I.
Hum. Mol. Genet. 4: 2175-2177.

Tavormina P.L., Bellus G.A., Webster M.K., Bamshad M.J., Fraley A.E., McIntosh I., Szabo J., Jiang W., Jabs E.W., Wilcox W.R., Wasmuth J.J., Donoghue D.J., Thompson L.M., Francomano C.A., 1999
A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 (FGFR3) gene.
Am. J. Hum. Genet. 64: 722-731.

Theillet C., Adélaïde J., Louason G., Bonnet-Dorion F., Jacquemier J., Adnane J., Longy M., Katsaros D., Sismondi P., Gaudray P., Birnbaum D., 1993
FGFR1 and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers.
Genes Chrom. Cancer. 7: 219-226.

Thomas G., Hall M.N., 1997
TOR signalling and control of cell growth.
Cur. Op. Cell Biol. 9: 782-787.

Thorsteinsdottir U., Krosl J., Kroon E., Haman A., Hoang T., Sauvageau G., 1999
The oncoprotein E2A-Pbx1a collaborates with Hoxa9 to acutely transform primary bone marrow cells.
Mol. Cell. Biol. 19: 6355-6366.

Tlsty T.D., White A., and Sanchez J., 1992
Suppression of gene Amplification in human cell Hybrids.
Science. 255: 1425-1427.

Tomasson M.H., Williams I.R., Hasserjian R., Udomsakdi C., McGrath S.M., Schwaller J., Druker B., Gilliland D.G., 1999
TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor.
Blood. 5: 1707-1714.

Tomasson M.H., Sternberg D.W., Williams I.R., Carroll M., Cain D., Aster J.C., Ilaria R.L., Van Etten R.A., Gilliland D.G., 2000
Fatal myeloproliferation, induced in mice by TEL/PDGFβR expression, depends on PDGFβR tyrosines 579/581.
J. Clin. Inv. 105: 423-432.

Tomasson M.H., Williams I.R., Li S., Kutok J., Cain D., Gillessen S., Dranoff G., Van Etten R.A., Gilliland D.G., 2001
Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3.
Blood. 97: 1435-1441.

Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., Croce C.M., 1984
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.
Science. 226: 1097-1099.

Twigg S.R., Burns H.D., Oldridge M., Heath J.K., Wilkie A.O., 1998
Conserved use of a non-canonical 5’ splice site (/GA) in alternative splicing by fibroblast growth factor receptors 1, 2 and 3.
Hum. Mol. Genet. 7: 685-691.

U

Uckun FM., Herman-Hatten K., Crotty ML., Sensel MG., Sather HN., Ahlgren LT., Sarquis MB., Bostrom B., Nachman JB., Steinherz PG., Gaynon PS., Heerema N., 1998
Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;14)(q21;q23) chromosomal translocation.
Blood. 92: 810-821.

Ugolini F., Adélaïde J., Charafe-Jauffret E., Nguyen C., Jacquemier J., Jordan B., Birnbaum D., Pébusque M.J., 1999
Differential expression assay of chromosome arm 8p genes identifies Frizzlzed-related (FRP1/FRZB) and Fibroblast growth factor receptor 1 (FGFR1) as candidate breast cancer genes.
Oncogene. 18: 1903-1910.

Ullrich A., and Schlessinger J., 1990
Signal transduction by receptors with tyrosine kinase activity.
Cell. 61: 203-212.

V

Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M., 1996
Suppression of TNF-α-induced apoptosis by NFκB.
Science. 274: 787-789.

van de Rijn M., Heimfeld S., Spangrude G.J., Weissman I.L., 1989
Mouse hematopoietic stem-cell antigen Sca-1 is a member of the Ly-6 antigen family
Proc. Natl. Acad. Sci. 86: 4634-4638.

van den Berg H., Kroes W., van der Schoot C.E., Dee R., Pals S.T., Bouts T.H.M., Slater R.M., 1996
A young child with acquired t(8;9)(p11;q34): additional proof that 8p11 is involved in mixed myeloid/T lymphoid malignancies.
Leukemia. 10: 1252-1253.

Vandergoten P., Janssen M., Madoe V., Vanstraelen D., 1998
A myeloproliferative disorder with eosinophilia, a translocation t(8;9)(p22;23) and a cerebellar degeneration in regression with interferon alpha therapy.
Acta Hematol. 100 (Suppl.): 8.

van der Maarel SM., Scholten IH., Hubert I., Philippe C., Suijkerbuijk RF., Gilgenkrantz S., Kere J., Cremers FPM., Ropers H.H., 1996
Cloning and characterization of DXS66773E, a candidate gene for X-linked mental retardation in Xq13.1.
Hum. Mol. Genet. 5: 887-897.

Van Etten R.A., 2001a
Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models
Cur. Op. Hematol. 8: 224-230.

Van Etten R.A., 2001b
Retroviral transduction models of Ph+ leukemia: advantages and limitations for modeling human hematological malignancies in mice.
Blood Cells Mol. Dis. 27: 201-205.

van Hemert M.J., de Steensma H.Y., van Heusden G.P.H., 2001
14-3-3 proteins: key regulators of cell division, signalling and apoptosis.
BioEssays. 23: 936-946.

Vannier J.P., Bizet M., Bastard C., Bernard A., Ducastelle T., Tron P., 1984
Simultaneous occurrence of a T-cell lymphoma and a chronic myelogenous leukemia with an unusual karyotype.
Leukemia Res. 8: 647-657.

Vickers M., 1996
Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data.
Br. J. Haematol. 94: 1-4.

Vogt P.K., 2001
PI 3-kinase, mTOR, protein synthesis and cancer.
Trends Mol. Med. 7: 482-484.

Von Gise A., Lorenz P., Wellbrock C., Hemmings B., Berberich-Siebelt F., Rapp U.R., Troppmair J., 2001
Apoptosis suppression by Raf-1 and MEK1 requires MEK and phosphatidylinositol 3-kinase-dependent signals
Mol. Cell. Biol. 21: 2324-2336.

Voss J., Posern G., Hannemenn J.R., Wiedemann L.M., Turhan A.G., Poirel H., Bernard O., Adermann K., Kardinal C., Feller S.M., 2000
The leukaemic oncoproteins Bcr-Abl and tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways.
Oncogene. 19: 1684-1690.

W

Wai D.H., Knezevich S.R., Lucas T., Jansen B., Kay R.J., Sorensen P.H.B., 2000
The ETV6-NTRK3 gene fusion encodes a chimeric protein kinase that transforms NIH3T3 cells.
Oncogene. 19: 906-915.

Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., Williams R.L., 2000
Structural determinants of phosphoinositide-3-kinase by wortmannin, LY294002, quercetin, myricetin, and staurosporine.
Mol. Cell. 6: 909-919.

Wallenius V., Hisaoka M., Helou K., Levan G., Mandahl N., Meis-Kindblom J.M., Kindblom L.G., Jansson J.O., 2000
Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracelular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.
Am. J. Pathol. 156: 821-829.

Wang J-K., Gao G., and Goldfarb M., 1994
Fibroblast growth factor receptors have different signaling and mitogenic potentials.
Mol. Cell. Biol.. 14: 181-188.

Wang J-K., Xu H., Li HC., Goldfarb M., 1996
Broadly expressed SNT-like proteins link FGF receptor stimulation to activators of ras.
Oncogene. 13: 721-729.

Wang J-K., and Goldfarb M., 1997
Amino acid residues which distinguish the mitogenic potentials of two FGF receptors.
Oncogene. 14: 1767-1778.

Wang H.G., Rapp U.R., Reed J.C., 1996
Bcl-2 targets the protein kinase Raf-1 to mitochondria.
Cell. 87: 629-638.

Wang CY., Mayo M.W., Baldwin A.S., 1996
TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFκB.
Science. 274: 784-787.

Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S., 1998
NFκB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science. 281: 1680-1683.

Wang Z., Glück S., Zhang L., Moran M.F., 1998
Requirement for phospholipase C-γ1 enzymatic activity in growth factor-induced mitogenesis.
Mol. Cell. Biol. 18: 590-597.

Webster MK., and Donoghue DJ., 1996a
Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
EMBO J. 15: 520-527.

Webster MK., D'Avis PY., Robertson SC., Donoghue DJ., 1996b
Profound ligand- independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for the lethal skeletal dysplasia, thanatophoric dysplasia type II.
Mol. Cell. Biol. 16: 4081-4087.

Webster MK., and Donoghue DJ., 1997a
FGFR activation in skeletal disorders: too much of a good thing.
Trends. In. Genet. 13: 178-182.

Webster MK., and Donoghue DJ., 1997b
Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain.
Mol. Cell. Biol. 17: 5739-5747.

Weide R., Rieder H., Mehraein Y., Wolf M., Kaiser U., Seifart U., Görg C., Havemann K., 1997
Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease.
Br. J. Haematol. 96:117-123.

Weiner DB., Liu J., Cohen JA., Williams WV., Greene M., 1989
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
Nature. 339: 230-231.

Weissman I.L., 2000
Translating stem and progenitor cell biology to the clinic: barriers and opportunities.
Science. 287: 1442-1446.

Wellmann A., Doseeva V., Butscher W., Raffeld M., Fukushima P., Stetler-Stevenson M., Gardner K., 1997
The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts.
FASEB J. 11: 965-972.

Wells R.A., Catzavelos C., Kamel-Reid S., 1997
Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia.
Nat. Genet. 17: 109-113.

Weng Q.P., Andrabi K., Klippel A., Kozlowski M.T., Williams L.T., Avruch J., 1995
Phosphatidylinositol 3-kinase signals activation of p70 S6 kinase in situ through site-specific p70 phosphorylation.
Proc. Natl. Acad. Sci. 92: 5744-5748.

Werner S., Weinberg W., Liao X., Peters K.G., Blessing M., Yuspa S.H., Weiner R.L., Williams L.T., 1993
Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation.
EMBO J. 12: 2635-2643.

Westervelt P., Ley T., 1999
Seed versus soil: the importance of the target cell for transgenic models of human leukemias.
Blood. 93: 2143-2148.

Wiedemann M., Trueb B., 2000
Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors.
Genomics. 69: 275-279.

Wilbanks A.M., Mahajan S., Frank D.A., Druker B.J., Gilliland D.G., Carroll M., 2000
TEL/PDGFβR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins.
Exp. Hematol. 28: 584-593.

Wilkie AOM., Slaney SF., Oldridge M ., Poole MD., Ashworth GJ., Hockley AD., Hayward RD., David DJ., Pulleyn LJ., Rutland P., Malcolm S., Winter RM., Reardon W., 1995a
Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome.
Nature Genet. 9: 165-172.

Wilkie A.O.M., Morriss-Kay G.M., Jones E.Y., Heath J.K., 1995b
Functions of fibroblast growth factors and their receptors.
Curr. Biol. 5: 500-507.

Wilks A.F., 1993
Protein tyrosine kinase growth factor receptors and their ligands in development, differentiation, and cancer.
Adv. Cancer Res. 60: 43-73.

Willis TG., Dyer MJS., 2000
The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies.
Blood. 96: 808-822.

Wilson G., Frost L., Goodeve A., Vandenberghe E., Peake I., Reilly J., 1997
BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia.
Blood. 89: 3064.

Wong E.S.M., Lim J., Low B.C., Chen Q., Guy G.R., 2001a
Evidence for direct interaction between Sprouty and Cbl.
J. Biol. Chem. 276: 5866-5875.

Wong S., Witte O.N., 2001b
Modeling philadelphia chromosome positive leukemias.
Oncogene. 20: 5644-5659.

Wu R., Connolly D., Ngelangel C., Bosch X., Munoz N., Cho K.R., 2000
Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.
Oncogene. 19: 5543-5546.

Wymann MP., Pirola L., 1998
Structure and function of phosphoinositide 3-kinases.
Biochim. Biophys. Acta. 1436: 127-150.

X

Xiao S., Nalabolu S.R., Aster J.C., Ma J., Abruzzo L., Jaffe E.S., Stone R., Weissman S.M., Hudson T.J., and Fletcher J.A., 1998
FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia / lymphoma syndrome.
Nat.Genet. 18: 84-87.

Xu H., Lee KW., Goldfarb M., 1998
Novel recognition motif on fibroblast growth factor receptor mediates direct association and activation of SNT adapter proteins.
J. Biol. Chem. 273: 17987-17990.

Y

Yagasaki F., Wakao D., Yokoyama Y., Uchida Y., Murohashi I., Kayano H., Taniwaki M., Matsuda A., Bessho M., 2001
Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.
Cancer Res. 61: 8371-8374.

Yamaguchi T.P., Harpal K., Henkemeyer M., Rossant J., 1994
fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation.
Genes Dev. 8: 3032-3044.

Yang E., Zha J., Jockel E.J., Boise L.H., Thompson C.B., Korsmeyer S.J., 1995
Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.
Cell. 80: 285-291.

Yarden Y., Sliwkowski M.X., 2001
Untangling the ErbB signalling network.
Nature. 2: 127-137.

Yayon A., Klagsbrun M., Esko JE., Leder P., Ornitz DM., 1991
Cell surface heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.
Cell. 64: 841-848.

Yenush L., White MF., 1997
The IRS-signalling system during insulin and cytokine action.
BioEssays. 19: 491-500.

Yu K., Herr A.B., Waksman G., Ornitz D.M., 2000
Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.
Proc. Natl. Adad. Sci. 97: 14536-14541.

Yuan Z.Q., Sun M., Felman R.I., Wang G., Ma X.L., Jiang C., Coppola D., Nicosia S.V., Cheng J.Q., 2000
Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
Oncogene. 19: 2324-2330.

Z

Zha J., Harada H., Yang E., Jockel J., Korsmeyer S.J., 1996
Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL.
Cell. 87: 619-628.

Zhang B.X., Ren R., 1998
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony- stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Blood. 92: 3829-3840.

Zhang X., Wong R., Hao S.X., Pear W.S., Ren R., 2001a
The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
Blood. 97: 277-287.

Zhang X., Subrahmanyam R., Wong R., Gross A.W., Ren R., 2001b
The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
Mol. Cell. Biol. 21: 840-853.

Zhao R.C., Jiang Y., Verfaillie C.M., 2001
A model of human p210bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34+ cells with a BCR/ABL-containing retroviral vector.
Blood. 97: 2406-2412.

Zhou H., Li X.M., Meinkoth J., Pittman R.N., 2000
Akt regulates cell survival and apoptosis at a postmitochondrial level.
J. Cell Biol. 151: 483-494.

Zong W.X., Edelstein L.C., Chen C., Bash J., Gélinas C., 1999
The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis.
Genes Dev. 13: 382-387.

Zörnig M., Hueber A.O., Baum W., Evan G., 2001
Apoptosis regulators and their role in tumorigenesis.
Bioch. Biophys. Acta. 1551: F1-F37.

Zou H., Li Y., Liu X., Wang X., 1999
An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9.
J. Biol. Chem. 274: 11549-11556.

Created:
29/04/2002
Last updated:
20/01/2020
Authors:
Géraldine Guasch
Editors:
Marie-Paule Lefranc, Chantal Ginestoux